Report on the risk assessment of N-(1‑phenethylpiperidin-4-yl)-N-phenylacrylamide (acryloylfentanyl) in the framework of the Council Decision on new psychoactive substances. by unknown
20RISK ASSESSMENTS
Acryloylfentanyl
Report on the risk assessment 
of N-(1-phenethylpiperidin-4-yl)-N-
phenylacrylamide (acryloylfentanyl) 
in the framework of the Council Decision 
on new psychoactive substances
About this series
EMCDDA Risk Assessments are publications 
examining the health and social risks of 
individual new psychoactive substances.
The Risk Assessment Report consists of an 
analysis of the scientific and law enforcement 
information available on the new psychoactive 
substance under scrutiny and the implications 
of placing it under control. It is the outcome of 
a meeting convened under the auspices of the 
EMCDDA Scientific Committee.
This process is part of a three-step procedure 
involving information exchange/early warning, 
risk assessment and decision-making in the 
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Foreword
This publication presents the data and findings of the risk assessment on acryloylfentanyl 
(N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide), carried out by the extended Scientific 
Committee of the EMCDDA on 22 February 2017.
The Risk Assessment Report, which was submitted to the European Commission and the 
Council of the European Union on 24 February 2017, examines the health and social risks 
of the drug, information on international trafficking and the involvement of organised crime, 
as well as a consideration of the potential implications of subjecting the drug to control 
measures. Acryloylfentanyl is the thirteenth new psychoactive substance to be risk 
assessed under the terms of Council Decision 2005/387/JHA.
On the basis of the Risk Assessment Report — and on the initiative of the European 
Commission — on 25 September 2017 the Council decided that acryloylfentanyl should 
be subject to control measures across the Member States. This decision was adopted in 
the final stage of the three-step proceSs — early warning, risk assessment and control of 
new psychoactive substances — established by the Council Decision 2005/387/JHA. This 
legal framework allows the EU institutions and Member States to act on all new and 
potentially threatening narcotic and psychotropic drugs which appear on the European 
drug scene, with the EMCDDA and Europol, in collaboration with their respective networks 
playing a central role in the early detection of such substances as well as the harms 
caused by their use — information that underpins risk assessment, and, ultimately, 
decision-making.
In this respect we would like to acknowledge the excellent work done by the networks of 
the EMCDDA and Europol, as well as those of the EMA — the Reitox national focal points, 
Europol national units and the national competent authorities responsible for medicinal 
products — who played an essential role in collecting and providing national data.
Finally, we would like to thank all the participants in the risk assessment process for the 
high quality of work carried out. The resulting report is a valuable contribution at European 
level, which gives clear support to political decision-making.
Professor Dr Gerhard Bühringer  
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EMCDDA actions on monitoring and responding to new drugs
The EMCDDA has been assigned a key role in the detection and assessment of new drugs 
in the European Union under the terms of a Council Decision 2005/387/JHA on the 
information exchange, risk-assessment and control of new psychoactive substances.
It establishes a mechanism for the rapid exchange of information on new psychoactive 
substances and provides for an assessment of the risks associated with them in order to 
permit the measures applicable in the Member States for the control of narcotic and 
psychotropic substances to be applied also to new psychoactive substances.
The three-step process involves information exchange/early warning, risk assessment and 
decision-making (see below). More detailed information can be found in the section ‘Action 
on new drugs’ of the EMCDDA’s website:  
www.emcdda.europa.eu/activities/action-on-new-drugs
Council Decision 2005/387/JHA of 10 May 2005 on the information exchange,
risk-assessment and control of new psychoactive substances:
I. Information exchange
Early-warning system (EWS) EMCDDA–Europol Joint Reports
III. Decision-making Council Decisions on control
II. Risk assessment EMCDDA Risk Assessments
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Europol–EMCDDA Joint Report on acryloylfentanyl 
(N‑(1‑phenethylpiperidin‑4‑yl)‑N‑phenylacrylamide) — 
a summary
Europol–EMCDDA Joint Report on a new psychoactive substance: 
N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide — in accordance with Article 5 of 
Council Decision 2005/387/JHA on the information exchange, risk assessment and 
control of new psychoactive substances
In September 2016, the EMCDDA and Europol examined the available information on 
a new psychoactive substance N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide, 
commonly known by the abbreviation ‘acryloylfentanyl’, through a joint assessment based 
upon the following criteria: (1) the amount of the material seized; (2) evidence of organised 
crime involvement; (3) evidence of international trafficking; (4) analogy with better-studied 
compounds; (5) evidence of the potential for further (rapid) spread; and (6) evidence of 
cases of serious intoxication or fatalities.
The EMCDDA and Europol agreed that the information available on acryloylfentanyl 
satisfied criteria 4 and 6. The two organisations therefore concluded that sufficient 
information has been accumulated to merit the production of a Joint Report on 
acryloylfentanyl as stipulated by Article 5.1 of the Decision. Accordingly, the NFPs, the 
Europol national units (ENUs), the EMA and the World Health Organization (WHO) were 
formally asked to provide the relevant information within six weeks from the date of the 
request, i.e. by 19 October 2016.
The resulting Joint Report on acryloylfentanyl was submitted to the Council, the 
Commission and the EMA on 16 November 2016. The report concluded that the health and 
social risks, caused by the use of, the manufacture of, and traffic in acryloylfentanyl, as well 
as the involvement of organised crime and possible consequences of control measures, 
could be thoroughly assessed through a risk assessment procedure as foreseen by 
Article 6 of Council Decision 2005/387/JHA.
The full text of the Joint Report can be found at: 
www.emcdda.europa.eu/publications/joint-reports/acryloylfentanyl
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This risk assessment report presents the summary 
findings and the conclusion of the risk assessment 
carried out by the extended Scientific Committee of the 
European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA) on the new psychoactive 
substance N-(1-phenethylpiperidin-4-yl)-N-
phenylacrylamide (commonly known as acryloylfentanyl 
or acrylfentanyl). The report is intended for policy makers 
and decision makers in the institutions of the 
European Union.
The report has been prepared and drafted in accordance 
with the conceptual framework and the procedure set 
out in the risk assessment operating guidelines (1). It is 
written as a stand-alone document, which presents 
a summary of the information considered during the 
detailed analysis of the scientific and law enforcement 
data available at this time. The conclusion section of the 
report summarises the main issues addressed and 
reflects the opinions held by the members of the 
Scientific Committee. A list of the information resources 
considered by the Scientific Committee, including 
a detailed technical report on acryloylfentanyl, is 
provided below.
The risk assessment has been undertaken in compliance 
with Article 6 of Council Decision 2005/387/JHA of 
10 May 2005 on the information exchange, risk 
assessment and control of new psychoactive 
substances (2) (hereafter ‘Council Decision’). The 
Council Decision establishes a mechanism for the rapid 
exchange of information on new psychoactive 
(1) EMCDDA (2010), Risk assessment of new psychoactive substances: 
Operating guidelines, Publications Office of the European Union, 
Luxembourg. Available at: http://www.emcdda.europa.eu/html.cfm/
index100978EN.html
(2) OJ L 127, 20.5.2005, p. 32.
substances (hereafter ‘EU Early Warning System’ (3)) 
that may pose public health and social threats, including 
those related to the involvement of organised crime. 
Thus, it allows the institutions of the European Union and 
the Member States to act on all new narcotic and 
psychotropic substances (4) that appear on the 
European Union drug market. The Council Decision also 
provides for an assessment of the risks associated with 
these new psychoactive substances so that, if 
necessary, control measures can be applied in the 
Member States for narcotic and psychotropic 
substances (5).
Acryloylfentanyl was formally notified on 7 July 2016 by 
the EMCDDA on behalf of the Danish national focal 
point, in accordance with Article 4 of the Council 
Decision. The notification related to the seizure of 
a capsule made on 11 May 2016 by the Department of 
Forensic Psychiatry, Aalborg Psychiatric Hospital, 
Aalborg. Following an assessment of the available 
information on acryloylfentanyl, and in accordance with 
Article 5 of the Council Decision, on 17 November 2016 
the EMCDDA and Europol submitted a Joint Report on 
acryloylfentanyl (6) to the Council of the European Union, 
(3) The information exchange mechanism laid down by the Council 
Decision is operationalized as the European Union Early Warning 
System on New Psychoactive Substances (‘EU Early Warning System’). 
It is operated by the EMCDDA and Europol in partnership with the 
Reitox national focal points and Europol National Units in the Member 
States, the European Commission, and the European Medicines 
Agency.
(4) According to the definition provided by the Council Decision, a ‘new 
psychoactive substance’ means a new narcotic drug or a new 
psychotropic drug in pure form or in a preparation; ‘new narcotic drug’ 
means a substance in pure form or in a preparation that has not been 
scheduled under the 1961 United Nations Single Convention on 
Narcotic Drugs, and that may pose a threat to public health 
comparable to the substances listed in Schedule I, II or IV; ‘new 
psychotropic drug’ means a substance in pure form or in 
a preparation that has not been scheduled under the 1971 United 
Nations Convention on Psychotropic Substances, and that may pose 
a threat to public health comparable to the substances listed in 
Schedule I, II, III or IV.
(5) In compliance with the provisions of the United Nations Single 
Convention on Narcotic Drugs of 1961 and the United Nations 
Convention on Psychotropic Substances of 1971.
(6) EMCDDA and Europol (2016), EMCDDA–Europol Joint Report on 
a new psychoactive substance: N-(1-phenethylpiperidin-4-yl)-N-
phenylacrylamide (acryloylfentanyl), EMCDDA, Lisbon. Available at: 
http://emcdda.europa.eu/publications/joint-reports/acryloylfentanyl
RISK ASSESSMENTS | Acryloylfentanyl Risk Assessment Report
7/50
the European Commission, and the European Medicines 
Agency (EMA). Taking into account the conclusion of the 
Joint Report, and in accordance with Article 6 of the 
Council Decision on 23 January 2017, the Council 
formally requested that ‘the risk assessment should be 
carried out by the extended Scientific Committee of the 
EMCDDA and be submitted to the Commission and the 
Council within 12 weeks from the date of this 
notification’.
In accordance with Article 6.2, the meeting to assess the 
risks of acryloylfentanyl was convened under the 
auspices of the Scientific Committee of the EMCDDA 
with the participation of two additional experts 
designated by the Director of the EMCDDA, acting on 
the advice of the Chairperson of the Scientific 
Committee, chosen from a panel proposed by Member 
States and approved by the Management Board of the 
EMCDDA. The additional experts were from scientific 
fields that were either not represented, or not sufficiently 
represented on the Scientific Committee, and whose 
contribution was necessary for a balanced and 
adequate assessment of the possible risks of 
acryloylfentanyl, including health and social risks. 
A further four experts participated in the risk 
assessment: two experts from the Commission, one 
expert from Europol, and one expert from the European 
Medicines Agency (EMA). The meeting took place on 
22 February 2017 at the EMCDDA in Lisbon. The risk 
assessment was carried out on the basis of information 
provided to the Scientific Committee by the Member 
States, the EMCDDA, Europol and the EMA. A list of the 
extended Scientific Committee, as well as the list of 
other participants attending the risk assessment 
meeting, is annexed to this report (p. 48).
For the risk assessment, the extended Scientific 
Committee considered the following information 
resources:
 § Technical report on N-(1-phenethylpiperidin-4-yl)-N-
phenylacrylamide (acryloylfentanyl) (Annex 1);
 § EMCDDA–Europol Joint Report on a new psychoactive 
substance: N-(1-phenethylpiperidin-4-yl)-N-
phenylacrylamide (acryloylfentanyl) (6);
 § Open source information including scientific articles, 
official reports, grey literature, internet drug 
discussion forums and related websites (hereafter 
‘user websites’);
 § Additional information provided during the course of 
the risk assessment meeting by the participants;
 § The EMCDDA operating guidelines for the risk 
assessment of new psychoactive substances (1); and,
 § Council Decision 2005/387/JHA of 10 May 2005 on 
the information exchange, risk assessment and 
control of new psychoactive substances (2).
Finally, it is important to note that this risk assessment 
report contains a discussion of the available information 
on serious adverse events such as acute intoxications 
(typically presenting to hospital emergency 
departments) and deaths associated with 
acryloylfentanyl. Such information is critical to the 
identification of emerging toxicological problems 
associated with new psychoactive substances within 
the European Union. In this context, it is important to 
recognise that the capacity to detect, identify, and report 
these events differ both within and between Member 
States. In the past few years, programmes have been 
introduced in some Member States to strengthen these 
capacities. The EMCDDA’s toxicovigilance system, which 
constitutes a central component of the EU Early Warning 
System, has also been strengthened resulting in more 
information being available regarding serious adverse 
events associated with new psychoactive substances. 
Nonetheless, it is likely that these events remain 
under-detected and under-reported.
Physical, chemical and 
pharmacological description
N-(1-Phenethylpiperidin-4-yl)-N-phenylacrylamide 
(acryloylfentanyl) is an acrylamide derivative of 
4-anilinopiperidine and is an unsaturated analogue of 
fentanyl, which is a propionamide (Figure 1). 
Acryloylfentanyl contains one basic nitrogen atom in the 
piperidine ring readily forming salts with organic or 
inorganic acids. All the fentanyl derivatives have in 
common an aryl group linked to 
a 4-N-acetylanilinopiperidine.
Acryloylfentanyl is known from the scientific literature 
and is a close structural relative of fentanyl. Fentanyl is 
a fast but short-acting synthetic opioid that has been 
widely used in clinical practice including as an adjunct to 
general anaesthesia during surgery and for 
postoperative pain management. Acryloylfentanyl is also 
structurally related to acetylfentanyl, which was the 
subject of an EMCDDA–Europol Joint Report in 2015 
following more than 30 deaths in Europe.
Pharmacologically, acryloylfentanyl is an opioid.
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FIGURE 1  















Molecular mass 334.46 336.48
Synthetic opioids like fentanyl and related 
4-anilinopiperidine derivatives are potent analgesics. 
Initially developed in the 1960’s, a small number of this 
family of compounds — alfentanil, fentanyl, sufentanil 
and remifentanil — are widely used in human medicine 
as adjuncts to general anaesthesia during surgery and 
for pain management. They are available in a wide 
variety of formulations, such as tablets, transdermal 
patches, lozenges, liquid for injection and nasal sprays. 
Some are also used in veterinary medicine as general 
anaesthetics, to immobilise large animals, and for pain 
management. 
Fentanyl analogues first emerged on the illicit drug 
market in the United States of America in 1979. At the 
time they were not controlled under drug legislation. 
They were manufactured in clandestine laboratories and 
sold on the heroin market as heroin or ‘synthetic heroin’. 
A total of 14 fentanils are currently scheduled under the 
1961 Single Convention on Narcotic Drugs.
The analgesic activity of the fentanils is due to their 
activation of opioid receptors, in particular, the µ-opioid 
receptor. Besides their analgesic properties, a notable 
feature associated with µ-opioid receptor agonists is 
that they induce dose-dependent respiratory depression, 
in which overdose can be life-threatening. Other 
additional pharmacological effects include miosis, 
sedation, bradycardia, hypothermia, constipation, 
physical dependence, and changes in mood such as 
euphoria.
Similar to other fentanils, several synthetic routes to 
produce acryloylfentanyl are available in the scientific 
literature and have been published on the internet. Most 
of these are straightforward, make use of common 
laboratory equipment and precursors, and require only 
basic knowledge of chemistry. However, due to the high 
potency of acryloylfentanyl there is a serious risk of 
severe poisoning following accidental exposure during 
its manufacture. Extreme care must be taken when 
carrying out the final synthetic step as well as when 
purifying and handling the substance.
Acryloylfentanyl as free base or as its hydrochloride salt 
may occur as solids. There is no solubility data on 
acryloylfentanyl or its hydrochloride salt; however due to 
its close similarity to fentanyl, the free base is expected 
to be poorly soluble in water and highly lipophilic. 
In Europe, acryloylfentanyl has usually been seized as a 
liquid — sold in ready-to-use nasal spray solutions 
which are typically unlabelled — and as a powder. It has 
also been seized as tablets.
The analytical identification of acryloylfentanyl in 
physical and biological samples is possible using several 
analytical techniques. 
Immunoassays tests developed for morphine-type 
opioids are unlikely to give positive responses to 
acryloylfentanyl; while there is no information on 
whether acryloylfentanyl will give positive responses to 
immunoassays developed for fentanils. There is no 
information on the reaction of acryloylfentanyl to 
presumptive colour tests. The analytical identification of 
acryloylfentanyl should be made using techniques for 
which analytical data has been established: FT-IR, 
1H and 13C NMR, DEPT and two dimensional NMR (COSY 
and HSQC) and GC-MS and QTOF-MS (7). 
(7) FT-IR: Fourier transform infra-red; 1H and 13 C NMR: hydrogen-1 and 
carbon 13 nuclear magnetic resonance; DEPT: Distortionless 
enhancement by polarization transfer; COSY: Homonuclear 
correlation spectroscopy; HSQC: Heteronuclear single quantum 
correlation; GC-MS: Gas chromatography–mass spectrometry; EI: 
Electron ionization; QTOF: Quadrupole Time of Flight.
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The availability of analytical reference material is 
important for correct identification and for facilitating 
the quantification of acryloylfentanyl in physical and 
biological samples; such reference materials are 
commercially available. It should be noted that 
concentrations in blood samples can be in the sub-
nanogram range. 
As acryloylfentanyl has only been on the drug market for 
a short period of time it may not be part of most drug 
screenings and therefore may be undetected and/or 
underreported.
Route of administration and dosage
Acryloylfentanyl can be administered orally as a powder, 
as tablets, or as a solution; it can also be administered 
intranasally or sublingually via spray or snorted 
(insufflated); inhaled by vaporising e-liquid type 
solutions (‘vaping’); inhaled by smoking or vaporising the 
‘free base’; administered transdermally, and injected.
In the acute intoxications suspected to involve 
acryloylfentanyl that were reported to the EMCDDA, the 
most common route of administration was intranasally 
using a nasal spray. Less commonly, snorting of powder 
or crushed tablets, oral administration of tablets, and 
injection of a ‘nasal solution’ were also reported.
From the limited data available it is not possible to 
discern the ‘typical’ dosages administered by users. 
While a range of doses have been reported, these 
appear to differ depending on factors such as the route 
of administration, the tolerance of the users, the use of 
other drugs, and the desired effects.
Analysis of the concentration of nasal spray solutions of 
acryloylfentanyl in Sweden suggests that 10 mL nasal 
spray bottles have been sold containing 20 mg of the 
substance; one actuation (spray) would appear to deliver 
a dose of 0.2 mg. However, given that a range of different 
products appear to have been sold, caution should be 
taken in generalising these findings.
For nasal sprays, doses of 0.0027 mg to 0.2 mg were 
reported on user websites.
Pharmacology
Data on the pharmacology of acryloylfentanyl are limited 
to studies investigating its functional activity at opioid 
receptors in vitro, and its anti-nociceptive properties 
in mice.
An in vitro study shows that the affinity of 
acryloylfentanyl for opioid receptors is similar to that of 
fentanyl, and somewhat greater than that of morphine. 
In vivo studies suggest that acryloylfentanyl is a more 
potent and longer lasting anti-nociceptive agent than 
fentanyl, and that it has a time-response profile more 
closely related to that of morphine. At comparable doses, 
the analgesic effect of fentanyl became insignificant at 
90-120 minutes, whilst acryloylfentanyl maintained 
analgesia for this same time period. Administration of 
naloxone reversed the antinociceptive activity of 
acryloylfentanyl in vivo, however, this effect was 
transient and analgesia from acryloylfentanyl returned 
after a period of time.
Acryloylfentanyl, as part of a series of compounds, was 
studied as a potential covalent receptor affinity label; the 
available data suggests that acryloylfentanyl does not 
cause irreversible binding to opioid receptors (at least in 
rodents).
There are no published studies on the pharmacokinetics 
of acryloylfentanyl. Due to its lipophilicity, 
acryloylfentanyl, like fentanyl, is expected to readily 
cross the blood-brain barrier and also diffuse into fat and 
other tissues and is thus likely to have a large volume of 
distribution. In addition, the pharmacokinetics and the 
metabolic pathway of acryloylfentanyl are expected to 
be similar to that of fentanyl or acetylfentanyl. As such, 
acryloylfentanyl could be predicted to undergo 
metabolism by hepatic CYP450 3A4 and CYP450 3A5 
isoenzymes.
It is expected that one of the main metabolites present 
in biological matrices is the ‘desphenethyl’ derivative of 
acryloylfentanyl, that is ‘acryloyl norfentanyl’. Amide 
hydrolysis (deacylation) is a minor pathway for fentanyl 
and probably an insignificant biotransformation for the 
acryloyl analogue. Terminal hydroxylation of the acyl 
chain, which is also a minor biotransformation step for 
fentanyl in humans, produces what is often called 
‘hydroxyfentanyl’ but such a hydroxylation cannot take 
place in case of acryloylfentanyl.
There is some information on the biological activity of 
two potential metabolites of acryloylfentanyl. An in vitro 
study assessing the opioid-like activity of several 
fentanyl metabolites found that N-phenyl-1-(2-
phenylethyl)piperidin-4-amine (4-ANPP) and 
4-anilinopiperidine were less potent than either 
morphine or fentanyl by several orders of magnitude. 
The only metabolite showing significant activity in this 
study was a phenolic derivative hydroxylated at the 
4-position of the phenylethyl moiety of fentanyl, the 
activity of which was found to lie between morphine and 
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pethidine. This implies that the corresponding phenolic 
metabolite of acryloylfentanyl, if formed, may have some 
level of opioid activity and thus may contribute to the 
biological, including toxicological, properties of the 
parent substance. No information was found in the 
published literature regarding two other potential 
metabolites of acryloylfentanyl: the desphenethyl 
derivative of acryloylfentanyl and nor-acryloylfentanyl.
Inter-individual genetic variability in 
metabolising enzymes
There is no information on the inter-individual genetic 
variability in metabolising enzymes for acryloylfentanyl.
Interactions with other substances, medicines, 
and other forms of interactions
Should acryloylfentanyl be metabolised by CYP450 3A4 
and CYP450 3A5 isoenzymes, then the use of this 
substance with strong or moderate inhibitors of these 
isoenzymes (such as ketoconazole, fluconazole, 
clarithromycin, erythromycin, indinavir, ritonavir and 
saquinavir) may result in increased plasma 
concentration of acryloylfentanyl which could be 
toxicologically significant. Overall, this could increase 
the risk of poisoning including potentially fatal 
respiratory depression.
The concomitant use of other central nervous system 
(CNS) depressants with opioid analgesics, including 
other opioids, sedatives/hypnotics (such as the 
benzodiazepines and the z-drugs), ethanol (alcohol), 
gabapentinoids (pregabalin and gabapentin), 
tranquillisers, sedating anti-histamines, and skeletal 
muscle relaxants may produce additive depressant 
effects. Of note in this respect is that polydrug use was 
common in the deaths reported to the EMCDDA, 
including the use of other CNS depressants such as 
benzodiazepines, pregabalin, gabapentin and ethanol.
The use of fentanyl with serotoninergic agents, such as 
Selective Serotonin Re-uptake Inhibitors (SSRIs) (the 
most commonly prescribed antidepressants) or 
Serotonin Norepinephrine Re-uptake Inhibitors (SNRIs) 
or Monoamine Oxidase Inhibitors (MAOIs) has been 
associated with serotonin syndrome, a potentially 
life-threatening condition. This association is likely to 
extend to illicit drugs which act on the serotonergic 
system. It is not known if this association is also seen 
with acryloylfentanyl.
Severe and unpredictable potentiation by MAOIs has 
been reported with opioid analgesics.
Similar to fentanyl, the use of partial opioid agonists/
antagonists (such as buprenorphine, nalbuphine, 
pentazocine) which have high affinity to opioid receptors 
but relatively low intrinsic activity could partially 
antagonise the effects of acryloylfentanyl and may 
induce withdrawal symptoms in people who are opioid 
dependent.
Psychological and behavioural effects
From the available data, it appears that the 
psychoactivity of acryloylfentanyl is similar to that of 
other opioid analgesics which includes relaxation and 
euphoria; at higher doses, profound intoxication can be 
expected.
Legitimate uses
Acryloylfentanyl has no established or acknowledged 
medical value or use (human or veterinary) in the 
European Union. There is no marketing authorisation 
(existing, ongoing or suspended) for acryloylfentanyl in 
the European Union nor in the Member States that 
responded to the information request from the European 
Medicines Agency (EMA) that was launched under 
Article 5 of the Council Decision. In addition, there is no 
information to suggest acryloylfentanyl is used for the 
manufacture of a medicinal product or an active 
pharmaceutical ingredient (API) of a medicinal product 
in the European Union. It should be noted that there is 
no European Union database on the synthetic routes of 
all registered medicinal products.
Acryloylfentanyl is used as an analytical reference 
standard and for use in scientific research. There are no 
reported uses of acryloylfentanyl as a component in 
industrial, cosmetic or agricultural products.
Chemical precursors that are used 
for the manufacture
Information on the chemical precursors and the 
synthetic methods employed for acryloylfentanyl 
detected on the drug market within the European Union 
is limited. Impurities detected in a seizure suggest that 
4-ANPP may be used as a precursor and triethylamine 
as an acid scavenger during the synthesis.
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The manufacture of acryloylfentanyl most likely relies on 
precursors and synthetic methods similar to those used 
for the manufacture of pharmaceutical fentanyl. 
Accordingly, methods developed for the synthesis of 
fentanyl are applicable to acryloylfentanyl. A one-step 
method uses 4-ANPP and propionyl chloride, both of 
which are readily available, for the manufacture of the 
substance. Other acylation methods that use an 
activated ester of acrylic acid can also be used. Use of 
a different acylating agent in the final acylation step 
could provide other fentanils.
The potential precursors of acryloylfentanyl are 4-ANPP, 
1-(2-phenylethyl)piperidin-4-one (NPP), acryloyl chloride, 
3-chloropropionyl chloride, N-phenyl-N-(piperidin-4-yl)
acrylamide and phenethyl halide. None of these 
precursors are included in Table I or Table II of the 
United Nations Convention against Traffic in Narcotic 
Drugs and Psychotropic Substances, 1988.
Theoretically, acryloylfentanyl could serve as a precursor 




The assessment of individual health risks includes 
consideration of the acute and chronic toxicity of 
acryloylfentanyl, as well as its dependence potential, 
and its similarities to and differences from other 
chemically or pharmacologically related substances.
It is important to note that when interpreting the 
information from acute intoxications and deaths 
reported by Member States as well as information from 
user websites, that individuals may have used other 
substances in addition to acryloylfentanyl. The presence 
of and/or interaction with other substances or pre-
existing health conditions may account for some of the 
reported effects.
Acryloylfentanyl may be used in combination with other 
drugs (intentionally or unintentionally). Information from 
the seizure of nasal sprays containing acryloylfentanyl 
show that these are typically sold as unlabelled bottles. 
In some cases users have also filled nasal sprays 
previously containing medicinal products with 
acryloylfentanyl. The lack of instructions and potential 
for accidental use by others poses an inherent risk of 
poisoning.
Limited data from seizures have shown that it may be 
encountered in combination with heroin and carfentanil 
or sold as other drugs such as fentanyl. Therefore, some 
users are unlikely to be aware of the exact substance(s) 
being ingested (by whatever route). This presents an 
inherent risk to the individuals.
Acryloylfentanyl is available as ready-to-use nasal sprays 
which typically contain milligram amounts of dissolved 
substance. The preparation of solutions containing 
milligram amounts of substance is inherently prone to 
mistakes in weighing and dilution which may lead to 
solutions with higher (or lower) concentrations. This may 
constitute an increased risk of acute toxicity to the 
individuals, which are unlikely to be able to control the 
exact dose of acryloylfentanyl being consumed.
Acute toxicity
The acute toxicity of acryloylfentanyl has been assessed 
in mice in one study which suggests that its acute 
toxicity is similar to that of fentanyl.
No studies were identified that have investigated the 
acute effects of acryloylfentanyl and/or its metabolites 
in humans. For fentanyl the estimated lethal dose in 
humans could be as low as 2 mg when injected 
intravenously.
Acute intoxications
Twenty-one acute intoxications suspected to involve 
acryloylfentanyl were reported to the EMCDDA by 
Sweden. These related to acute poisoning presentations 
to hospital emergency departments reported to the 
Swedish Poison Information Centre. They were not 
analytically confirmed in biological samples.
Where known, acryloylfentanyl was usually administered 
intranasally using nasal sprays. To a lesser extent 
powders or crushed tablets were snorted or tablets 
taken orally. In one case a nasal solution was injected.
Of the acute intoxications, 18 (86 %) were male, three 
(14 %) were female. The mean age of the male cases for 
which an age was known was 35 years (median 29) and 
ranged from 22 to 44 years (n=7); for the female cases 
the ages were 22, 23, and 40 years. All 21 cases 
required treatment in hospital. Thirteen (62 %) were 
classified by the poison centre as life-threatening and 
eight were classified as non-life threatening. Use of the 
antidote naloxone was reported in eight of the cases, 
with apparent reversal of the poisoning reported in four 
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of these cases. In 10 cases it was reported that the 
patient recovered; the outcome was unknown in the 
remaining 11 cases.
Reported clinical features included: miosis, 
unconsciousness, and respiratory depression; 
tachycardia, somnolence, restlessness, and nausea/
vomiting were also reported. However, the lack of 
analytically confirmed drugs hinders the interpretation of 
this as other drugs may have caused or contributed to 
the symptoms observed. Nevertheless, such symptoms 
would be consistent with poisoning from an opioid, 
including a fentanil.
Deaths
A total of 47 deaths were reported by three Member 
States: Denmark (1), Estonia (3) and Sweden (43). In all 
cases, acryloylfentanyl was analytically confirmed from 
post-mortem samples. No further information was 
available regarding the deaths in Estonia, and therefore 
these have been excluded in the analysis below.
The 44 deaths reported by Denmark and Sweden 
occurred between April and December 2016; with more 
than 70 % occurring in a three month period between 
June and August 2016.
Of these deaths, 38 were male (86 %) and six were 
female (14 %). The mean age of the males was 31 years 
(median 29) and ranged from 19 to 54 years; the mean 
age of the females was 42 years (median 43) and ranged 
from 29 to 50 years.
Circumstances and cause of death
In all deaths there was a lack of information regarding 
any symptoms experienced by the deceased prior to 
death.
In more than 70 % of the cases, the individuals were 
found dead or died in a home environment (their own or 
someone else’s). Consequently, it was not possible to 
identify or evaluate ante-mortem symptoms (especially 
in relation to acute intoxications); however, in three 
cases the deceased were described as being 
unconscious prior to death, and in one of these cases it 
was reported that the deceased lost consciousness 
10 minutes after using acryloylfentanyl.
The cause of death was available in 43 out of 44 cases. 
In at least 40 deaths, acryloylfentanyl was either the 
cause of death or is likely to have contributed to death 
(even in presence of other substances); in two of these 
deaths acryloylfentanyl was the sole substance 
detected. Six deaths were potentially suicidal in nature.
Acryloylfentanyl was quantified in all cases. Post-
mortem blood concentrations between 0.01 and 
5.0 ng/g blood were recorded.
A range of other substances were detected in 42 of the 
44 deaths, including: benzodiazepines, zopiclone, 
gabapentinoids (pregabalin and gabapentin), ethanol, 
cannabinoids (including synthetic cannabinoids), 
synthetic cathinones, amphetamines, antidepressants, 
and antipsychotics. In 38 of the deaths, acryloylfentanyl 
was the only opioid detected. In the remaining six cases, 
buprenorphine (2 deaths), oxycodone (1); oxycodone 
and hydrocodone (1); oxycodone and 4-fluoro-
isobutyrfentanyl (1); and, 4-chloro-isobutyrfentanyl (1) 
were detected. Due to their potency and associated 
analytical challenges, the presence of some other 
fentanils (e.g. carfentanil) cannot be completely 
excluded.
Overall, whilst other substances may have contributed 
some toxicity, a synergistic effect with acryloylfentanyl 
would have been likely (e.g. other central nervous 
system depressants such as ethanol, benzodiazepines, 
opioids, etc.). Nevertheless, the potent opioid nature of 
acryloylfentanyl means the primary toxic contribution 
could be attributed to the drug and death may not have 
occurred if acryloylfentanyl had not been used.
Ability to operate machinery and drive
There have been no studies of the effects of 
acryloylfentanyl on the ability to drive and operate 
machines. However, it is well established that opioid 
analgesics, such as fentanyl, impair the mental and 
physical ability required to drive and operate machines. 
This effect is likely to extend to acryloylfentanyl.
Chronic toxicity
No studies were identified that investigated the chronic 
health effects of acryloylfentanyl and/or its metabolites.
Abuse liability and dependence potential
There have been no studies that have investigated the 
dependence and/or abuse potential of acryloylfentanyl 
in animals or humans. Given what is currently known 
about the pharmacology of acryloylfentanyl, it is 
reasonable to assume that the substance has both 
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a potential for abuse and dependence. Further research 
will be required in order to determine such effects.
Public health risks
The public health risks associated with acryloylfentanyl 
may be categorised in terms of patterns of use (extent, 
frequency, route of administration, etc.); availability and 
quality of the drug; information, availability and levels of 
knowledge amongst users; and, negative health 
consequences. Detailed information, including data on 
sporadic versus chronic use, that allow for 
a determination of public health risks associated with 
acryloylfentanyl are not available. In addition, risk of 
accidental exposure needs to be considered.
Extent, frequency, and patterns of use
The available data suggests that acryloylfentanyl is sold 
online in small and wholesale amounts as a ‘research 
chemical, typically as a powder and as ready-to-use 
nasal sprays. Acryloylfentanyl may also be sold on the 
illicit opioid market, as suggested by seizures where it 
was found in mixtures with heroin and carfentanil. In 
these cases, it is reasonable to assume that some 
individuals may not be aware that they are consuming 
acryloylfentanyl.
There are no prevalence data on the use of 
acryloylfentanyl in the European Union or elsewhere, but 
the available information does not suggest wide use of 
the substance.
Based on its pharmacological effects and that it is sold 
as a ‘legal’ replacement to illicit opioids, it would be 
expected that acryloylfentanyl could be sought by those 
looking for substitutes to opioids, such as prescription 
opioids and heroin. It also appears that there is interest 
in this substance by some psychonauts.
Availability and quality on the market
While discussions on user websites suggest that 
acryloylfentanyl may have been available since 2014, the 
first analytical detection reported in Europe occurred in 
Denmark in May 2016. The most recent detection 
reported occurred in January 2017.
A total of 162 seizures have been reported by five 
Member States. The seizures occurred mostly at 
street-level as a powder (totalling 113 g) or a liquid 
(totalling 1 495 mL). While these quantities may appear 
relatively small they should be considered in the context 
of the high potency of acryloylfentanyl.
Characteristics and behaviour of users
No studies were identified that have examined the 
characteristics and behaviours of users of 
acryloylfentanyl.
Some users may be experimenting with this opioid by 
means of ready-to-use preparations; whilst others may 
seek to self-medicate pain or opioid-withdrawal 
symptoms. Some users, particularly those consuming 
acryloylfentanyl in mixtures with other illicit opioids such 
as heroin may not be aware that they are consuming the 
substance.
Data from the acute intoxications suspected to involve 
acryloylfentanyl shows that the most common route of 
administration were nasal sprays.
Data from user websites and deaths reported to the 
EMCDDA suggests that, similar to other opioids, 
acryloylfentanyl is typically used in the home 
environment.
Of note is that information from the deaths reported to 
the EMCDDA highlights that use of other opioids was 
uncommon; while polydrug use was common, including 
the use of other CNS depressants such as 
benzodiazepines, pregabalin, gabapentin and ethanol.
Nature and extent of health consequences
While information on the nature and extent of health 
consequences related to acryloylfentanyl are limited, 
there are a number of general considerations related to 
fentanils as a group.
Among other adverse effects, opioid analgesics, such as 
fentanyl, produce dose-dependent respiratory 
depression. This risk is greater in persons with no 
tolerance to opioids. Similar to other fentanils in 
overdose, the most serious acute risk arising from the 
use of acryloylfentanyl appears to be from profound and 
rapid respiratory depression, which can lead to apnoea, 
respiratory arrest, and death. This risk may be 
exacerbated given: the difficulty of diluting fentanils; the 
lack of experience of users with this new substance (in 
terms of a lack of familiarity with how to use it, the 
effects and dose of the substance); the concomitant use 
of other CNS depressants (such as other opioids, 
benzodiazepines, gabapentinoids, and ethanol); in some 
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cases no apparent tolerance to opioids; and, the 
environment in which the substance is used — typically 
in the home environment.
In the past few years, new dosage forms — such as 
ready-to-use nasal sprays, homemade transdermal 
patches and e-liquids for vaping — along with open 
sales on the surface web and darknet marketplaces add 
to the complexity of the problem caused by the fentanils. 
They have become easier to get hold of and easier to use. 
The Committee is concerned about whether the 
availability of ‘novel’ dosage forms has the potential to 
make the use of fentanils more socially acceptable.
An additional challenge in respect to reducing risk in 
users and potential users, is the balance between 
providing information to prevent harm and the 
unintended consequences of communicating the risks of 
opioids. There is evidence that using terms to describe 
them as ‘potent’, ‘strong’, ‘deadly’, and ‘toxic’ can lead 
some individuals to specifically seek out these 
substances. Such unintended promotion of the 
substances may also extend to former users and other 
groups.
Clinical experience with poisonings has found that the 
antidote naloxone will reverse poisoning (overdose) 
caused by acryloylfentanyl. However, repeated doses 
may be required to fully reverse poisoning. Clinical and 
community experience in treating poisonings caused by 
exposure to fentanils supports this assertion.
In the past two years a number of mass poisoning 
events over a short time period caused by fentanils have 
been reported particularly in the United States and 
Canada. These types of outbreaks have had the potential 
to overwhelm emergency departments and deplete 
stocks of naloxone. Stocks and availability of the 
naloxone, as well as adequacy of training in how to 
resuscitate poisoned patients both in clinical and 
community settings may need to be assessed. This 
might include a review of the availability of naloxone to 
users through take-home naloxone programmes.
Accidental exposure of acryloylfentanyl and other 
fentanils — such as skin contact, inhalation, or ingestion 
— also poses a serious risk of poisoning to those who 
may come into contact with the substances. This 
includes the family and friends of users, law 
enforcement, emergency personnel, medical and 
forensic laboratory personnel as well as custodial 
settings and postal services. In addition to exercising 
extreme caution when handling materials suspected to 
contain fentanils, working environments and personnel 
should be equipped with appropriate protective 
equipment. The antidote naloxone should be readily 
available to personnel in sufficient quantities; training in 
resuscitation and naloxone administration should also 
be available.
Adding to these challenges is evidence from Europe, the 
United States, and Canada that fentanils are being sold 
to unsuspecting users in/as heroin, counterfeit 
medicines (including commonly used opioid analgesics 
and benzodiazepines), cocaine, and other illicit drugs. As 
users will be unaware of this, it increases the risk of 
severe and fatal poisoning in both opioid users and 
especially other groups who may have no existing 
tolerance to opioids. Non-opioid users are unlikely to be 
aware of these risks and are unlikely to have access to 
community opioid overdose prevention programmes, 
including take-home naloxone programmes.
Long-term consequences of use
There is no information on the long-term consequences 
of use of acryloylfentanyl.
Conditions under which the substance is obtained 
and used
Based on the available data, it appears that one 
particularly important source of acryloylfentanyl was 
ready-to-use nasal sprays sold on the surface web in 
Sweden. This is also reflected in acute intoxications, 
where acryloylfentanyl was usually administered by 
nasal sprays.
Acryloylfentanyl has also been advertised on darknet 
marketplaces. In some cases the substance also 
appears to be sold by street-level drug dealers, including 
on the illicit opioid market.
Overall, acryloylfentanyl may be directly sought by some 
users, whilst others, such as those that purchase it at 
street-level, may be unaware that they are using 
acryloylfentanyl.
Social risks
While there have been no studies on the social risks of 
acryloylfentanyl, it is likely that some of the risks are 
similar to those seen with illicit opioids, such as heroin 
and prescription opioids including fentanyl.
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Individual social risks
There is no information on whether the use of 
acryloylfentanyl causes individual social risks; however, 
they may have some similarities with those associated 
with the use of illicit opioids, including fentanyl. These 
may impact on education or career, family or other 
personal and social relationships and may result in 
marginalisation.
Possible effects on direct social environment 
(e.g. neglect of family, violence)
There is no information on the possible effects of 
acryloylfentanyl on the direct social environment; 
however, they may have some similarities with those 
associated with the use of illicit opioids.
Possible effects on society as a whole 
(public order and safety, acquisitive crime)
There is no specific information on the possible effects of 
acryloylfentanyl on society as a whole.
As discussed above, accidental exposure of 
acryloylfentanyl and other fentanils — such as skin 
contact, inhalation, or ingestion — also poses a serious 
risk of poisoning to those who may come into contact 
with the substances. This includes the family and friends 
of users, law enforcement, emergency personnel, 
medical and forensic laboratory personnel as well as 
custodial settings and postal services. Where required, 
these risks should be assessed and appropriate 
procedures, training, and protective measures should be 
implemented. This may include training in resuscitation 
and adequate provision of naloxone to reverse poisoning.
Economic costs
There are no data on the effects of acryloylfentanyl in 
respect to its health and social costs. However, it is likely 
that even at low prevalence this drug has the potential to 
generate relatively high costs to health services.
Possible appeal to specific population groups
Whilst no specific examples are available on the 
possible appeal of acryloylfentanyl to specific user 
groups, it is reasonable to assume acryloylfentanyl may 
be sought by those looking for substitutes for illicit 
opioids, such as heroin and/or prescription opioids.
In addition, concerns exist over novel dosage forms 
— such as ready-to-use nasal sprays and e-liquids for 
vaping — which have the potential to make the use of 
fentanils easier (with similar effects to injecting) and 
more socially acceptable. Further research is required 
on this topic to better understand the risks.
Information on manufacturing, 
trafficking, distribution, and the level 
of involvement of organised crime
There is no specific information to suggest the 
involvement of organised crime or established criminal 
groups in the manufacture, distribution and supply of 
acryloylfentanyl.
Estonia and Sweden informed Europol that 
acryloylfentanyl was ordered in powder form from 
companies based in China. According to information 
from Swedish Police, the substance is then used to 
create ready-to-use unlabelled nasal spray products, 
with the nasal sprays also purchased from vendors in 
China. Swedish Police also reported that the open sale 
of fentanils on the internet appeared to generate large 
profits for retailers.
Information on any assessment 
in the United Nations system
The World Health Organization is the specialised United 
Nations agency designated for the evaluation of the 
medical, scientific and public health aspects of 
psychoactive substances under the Single Convention 
on Narcotic Drugs of 1961 and the Convention on 
Psychotropic Substances of 1971. At the time that the 
Joint Report was prepared (6), the World Health 
Organization informed the EMCDDA that 
acryloylfentanyl was not currently under assessment 
nor had it been under assessment by the United Nations 
system.
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Description of the control measures 
that are applicable in the Member 
States
Nine Member States (Cyprus, Denmark, Estonia, Finland, 
Ireland, Latvia, Lithuania, Sweden, and the United 
Kingdom) and Turkey reported that acryloylfentanyl is 
controlled under drug control legislation.
 § In Cyprus, acryloylfentanyl is controlled within the 
context of a generic clause which addresses fentanyl 
chemical groups.
 § In Denmark, acryloylfentanyl was included in an 
amendment of the Executive Order on Euphoriant 
Substances which entered into force on 24 November 
2016.
 § In Estonia acryloylfentanyl is controlled by way of 
generic definition.
 § In Finland, acryloylfentanyl is controlled as a narcotic 
as of 14 November 2016.
 § In Ireland, acryloylfentanyl is controlled under the 
Misuse of Drugs act 1977 (Schedule 1 (d) (iv), S.I. 251 
of 1987) by way of a generic definition.
 § In Latvia, acryloylfentanyl is included in the Cabinet 
Regulation N 847 'Regulations regarding Narcotic 
Substances, Psychotropic Substances and 
Precursors to be Controlled in Latvia' and the law 'On 
the Procedures for the Coming into force and 
Application of the Criminal Law'.
 § In Lithuania, acryloylfentanyl is controlled as of 
12 January 2017 by the Minister of Health Order No V-22.
 § In Sweden, acryloylfentanyl has been regulated as 
a narcotic since the 16 August 2016.
 § In the United Kingdom, acryloylfentanyl is controlled 
under the Misuse of Drugs Act 1971 by way of 
a generic definition.
 § In Turkey, acryloylfentanyl is controlled under Drug 
Law on Drugs numbered 2313 with the decree of 
Council of Ministers 2016/9712 dated 
27 December 2016.
Two Member States (Austria and Poland) reported that 
acryloylfentanyl is controlled under specific new 
psychoactive substances control legislation.
 § In Austria, acryloylfentanyl may be covered by the 
Austrian Act on New Psychoactive substances due to 
the presence of a phenethylamine moiety in the 
structure of the substance (8). 
(8) Austria reported that ‘Due to its phenethylamine [sic] structure 
acryloylfentanyl is unintentionally covered by the Austrian Act on New 
Psychoactive substances – but some experts might see it differently 
(https://www.ris.bka.gv.at/GeltendeFassung.
wxe?Abfrage=Bundesnormen&Gesetzesnummer=20007605)’.
 § In Poland, acryloylfentanyl is controlled according to 
the general definition of the ‘substitute drug’ which 
has been included to the Act of 8 October 2010 
amending the Act on counteracting drug addiction 
and the Act on State Sanitary Inspection (Journal of 
Laws ‘Dz.U.’ No. 213, item 1396). Article 44b of the 
above mentioned Act bans manufacturing or 
introducing substitute drugs to trade. 
In Norway, the importation of, trade in and marketing of 
acryloylfentanyl is controlled by the Medicines Act. 
Seventeen Member States (Belgium, Bulgaria, Croatia, 
Czech Republic (9), France, Germany, Greece, Hungary, 
Italy, Luxembourg, Malta, the Netherlands, Portugal, 
Romania, Slovakia, Slovenia, and Spain) reported that 
acryloylfentanyl is not subject to control measures at the 
national level.
Options for control and the possible 
consequences of the control measures
Under Article 9.1 of the Council Decision, the option for 
control that is available at European Union level is for the 
Member States to submit the new psychoactive 
substance acryloylfentanyl to control measures and 
criminal penalties, as provided for under their legislation, 
by virtue of their obligations under the Single Convention 
on Narcotic Drugs of 1961.
Relevant to these discussions is that around the time that 
acryloylfentanyl was subject to control measures in 
Sweden there was a marked decrease in the number 
deaths associated with the substance. In addition, in 
February 2017 it was announced that acryloylfentanyl will 
be controlled in China as of the 1 March 2017. This control 
measure may at least deter the open manufacture and 
sale of this substance by chemical companies, which are 
linked to the supply of the substance in Europe.
There are no studies on the possible consequences of 
such control measures on acryloylfentanyl. If this option 
of control is pursued, the Committee considers that the 
following consequences are possible. Some of these 
may apply to any new psychoactive substance.
 § This control option could be expected to limit the 
availability of acryloylfentanyl and hence the further 
expansion of the current open trade in this substance.
(9) The Czech Republic reported that an amendment of the Government 
Regulation No. 463/2013 Coll. is currently in process.
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 § A health consequence that might result from this 
control option is the benefit brought about by the 
presumed reduction in availability and use.
 § This control option could facilitate the detection, 
seizure and monitoring of acryloylfentanyl related to 
its unlawful manufacture, trafficking and use. In so 
doing, it could facilitate cooperation between the 
judicial authorities and law enforcement agencies 
across the European Union.
 § This control option would imply additional costs for 
the criminal justice system, including forensic 
services, law enforcement, and the courts.
 § This control option could lead to replacement with 
other (established or new) psychoactive substances, 
which may in themselves have public health 
consequences and social risks. Of relevance here is 
that since acryloylfentanyl was first notified in May 
2016, a further seven new fentanils have been 
detected on the drug market in Europe.
 § This control option could create an illicit market in 
acryloylfentanyl with the increased risk of associated 
criminal activity, including the involvement of 
organised crime.
 § This control option could impact on both the quality/
purity and price of any acryloylfentanyl still available 
on the illicit market. The extent to which this will 
impact on public health, criminality, or levels of use, is 
difficult to predict.
 § It is difficult to predict the impact of this control 
option on current or future research by the 
pharmaceutical or chemical industries.
 § In order to examine the consequences of control, the 
Committee wishes to note that it will be important to 
monitor for the presence of acryloylfentanyl on the 
market post-control, should this control option be 
pursued.
 § Aside from the option for control under those 
stipulated in Article 9.1 of the Council Decision, other 
options for control may be available to Member 
States. These may include restricting the importation 
and supply of the substance as some Member States 
have already done. 
Conclusion
N-(1-Phenethylpiperidin-4-yl)-N-phenylacrylamide 
(acryloylfentanyl) is a synthetic opioid and is structurally 
similar to fentanyl, a controlled substance widely used in 
medicine as an adjunct to general anaesthesia during 
surgery and for pain management. The available data 
suggests that acryloylfentanyl is a potent and long-
lasting antinociceptive agent acting on the 
opioid system. 
While the acute toxicity of acryloylfentanyl has not been 
determined, observations from a study conducted in 
mice suggest that it is similar to fentanyl. Its high 
potency constitutes a considerable risk of acute toxicity 
through respiratory depression.
Acryloylfentanyl has been available in Europe since at 
least April 2016 and has been detected in six Member 
States. The detected quantities are relatively small; 
however, they should be considered in the context of the 
high potency of acryloylfentanyl. 
Acryloylfentanyl is sold online as a ‘research chemical’, 
typically as a powder and as ready-to-use nasal sprays, 
in small and wholesale amounts. Limited information 
from seizures suggests that acryloylfentanyl may have 
also been sold on the illicit opioid market.
Typically, the substance has been administered by nasal 
spray, orally and by nasal insufflation. But other routes of 
administration, including injecting, vaping and 
transdermal administration have been reported. 
Concerns exist over ready-to-use nasal sprays and 
e-liquids for vaping which are novel ways of 
administering the drug, and which may have the 
potential to make the use of fentanils easier (with similar 
effects to injecting) and more socially acceptable. 
More than 20 acute intoxications suspected to be due to 
acryloylfentanyl have been reported. The clinical 
features were generally consistent with opioid-like 
toxicity and included life-threatening effects. 
Clinical experience suggests that naloxone works as an 
antidote to poisoning caused by acryloylfentanyl and it is 
likely that repeated doses are required. 
Forty-seven deaths have been reported by three 
Member States where acryloylfentanyl was detected 
post-mortem. In the majority of cases other drugs were 
also detected with acryloylfentanyl. In at least 40 deaths, 
acryloylfentanyl was either the cause of death or is likely 
to have contributed to death.
Accidental exposure to acryloylfentanyl, as well as to 
other fentanils, poses a risk to law enforcement, 
emergency personnel, medical and forensic laboratory 
personnel as well as to those in custodial settings and 
postal services. Specific risks and appropriate measures 
to reduce these risks should be identified and 
implemented. This may include appropriate protective 
equipment, training in resuscitation, and making 
naloxone readily available to relevant personnel in 
sufficient quantities in the event of poisonings.
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There is no information to suggest the involvement of 
organised crime in the manufacture, distribution 
(trafficking) and supply within the European Union. There 
is limited information on the chemical precursors and 
the synthetic routes used to manufacture the 
acryloylfentanyl detected within the European Union. 
Most of the synthetic routes are straightforward, make 
use of common laboratory equipment and readily 
available precursors, and require only basic knowledge 
of chemistry. The available data suggests that most of 
the acryloylfentanyl on the market in Europe has been 
produced by chemical companies based in China.
Acryloylfentanyl has no recognised human or veterinary 
medical use in the European Union nor, it appears, 
elsewhere. There are no indications that acryloylfentanyl 
may be used for any other purpose aside from as an 
analytical reference standard and in scientific research.
Acryloylfentanyl is not listed for control in the Single 
Convention on Narcotic Drugs of 1961 nor in the 
Convention on Psychotropic Substances of 1971. 
Acryloylfentanyl is not currently under assessment by 
the United Nations system. 
Nine Member States and Turkey control acryloylfentanyl 
under drug control legislation and two Member States 
and Norway control acryloylfentanyl under other 
legislation.
As for any new psychoactive substance, many of the 
questions related to acryloylfentanyl that are posed by 
the lack of data on the risks to individual health, risks to 
public health, and social risks, could be answered 
through further research. Areas where additional 
information would be important include studies on: 
rationale for use, prevalence and patterns of use 
(including studies that examine user groups and risk 
behaviours); the market; chemical profiling; complete 
pharmacological profiling; metabolic pathways; 
behavioural effects; acute and chronic toxicity; the 
potential interaction between acryloylfentanyl and other 
substances; the dependence and abuse potential; and 
the public health risks associated with its use.
The Committee notes that a decision to control 
acryloylfentanyl has the potential to bring with it both 
intended and unintended consequences. Potential 
intended consequences include reduced levels of 
availability and ultimately use. This may reduce the 
health and social risks and consequences arising from 
the use of acryloylfentanyl. It is important to recognise 
that a potential unintended consequence of control may 
be the manufacture and availability of other substances. 
Indeed, since 2016 at least seven fentanils and a 
number of other new opioids that may replace 
acryloylfentanyl are already being sold on the drug 
market. The implementation of control measures may 
also lead to the criminalisation of those who continue to 
use this substance with the possible attendant risks of 
socioeconomic stigmatisation and marginalisation. 
Finally the Committee notes that it is important to 
continue to collect and disseminate accurate 
information on acryloylfentanyl to users, practitioners, 
policy makers, decision makers and those who may be at 
risk of accidental exposure An additional challenge in 
respect to reducing risk in users and potential users, is 
the balance between providing information to prevent 
harm and the unintended consequences of 
communicating the risks of opioids. There is evidence 
that using terms to describe them as 'potent', 'strong', 
'deadly', and 'toxic' can lead some individuals to 
specifically seek out these substances. Such unintended 
promotion of the substances may also extend to former 
users and other groups.
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ANNEX 1  
Technical report on 
N‑(1‑phenethylpiperidin‑4‑yl)‑
N‑phenylacrylamide (acryloylfentanyl)
Report prepared by  
István Ujváry (1), Simon Elliott (2), Rita Jorge, Rachel 
Christie, Thomas Le Ruez, Helgi Valur Danielsson, 
Anabela Almeida, Ana Gallegos, Michael Evans-Brown, 
Roumen Sedefov. 
Data sources
The information in this technical report is derived from:
 § Data reported by the Member States, Turkey and 
Norway to the EMCDDA and Europol in accordance 
with Council Decision 2005/387/JHA on the 
information exchange, risk-assessment and control of 
new psychoactive substances (3); and, 
 § Data collected through systematic searches of open 
source information, including the scientific and 
medical literature, patents, official reports, grey 
literature, internet drug discussion forums and related 
websites, and online vendors selling acryloylfentanyl.
Search strategy 
Literature searches used both chemical structure and 
text queries in online databases; searches were 
conducted between September 2016 and 
February 2017. The retrieved publications were then 
scanned for additional relevant references (snowballing 
technique).
Chemical structure-based searches were done in 
SciFinder® (American Chemical Society, Chemical 
Abstract Service) and Reaxys® (Elsevier) databases 
using both the exact structure and the substructure of 
acryloylfentanyl (for the latter, substitutions on the 
phenyl, phenylethyl and piperidine moieties were 
allowed but the terminal propenamide group was 
defined by –CH=CH2 with explicit H-atoms. Structural 
searches in SureChEMBL patent database retrieved no 
relevant hits.
(1) EMCDDA contract ref. CT.16.SAT.0099.1.0.
(2) EMCDDA contract ref. CT.16.SAT.0100.1.0.
(3) OJ L 127, 20.5.2005, p. 32. 
Textual searches were conducted online in PubMed 
(National Center for Biotechnology Information), 
ScienceDirect (Elsevier), in popular English-language 
drug forums and in Google and Twitter. The search term 
used were: ‘acryloylfentanyl’, ‘acryl fentanyl’, ‘acryl 
fentanyl’, ‘fentanyl acroyl analogue’, ‘fentanyl 
propenamide’, ‘Acr-F opioid’, ‘Akrylfentanyl’ as well as for 
the following Chemical Abstract Service Registry 
Numbers (4): 82003-75-6, and 79279-03-1.
Textual searches for ‘acryloylfentanyl’ and 
‘acryloylfentanyl’ in Scopus® and Ovid® databases 
retrieved no relevant hits.
The internet was also searched in Google for the 
molecular formula string ‘C22H26N2O’.
In addition, reviews and selected papers from the vast 
literature on fentanyl, the close structural relative of 
acryloylfentanyl, were also consulted as were results of 
papers and patents retrieved by substucture searches in 
SciFinder® and Reaxys®.
Cursory though repeated inspections of English-
language internet forums covered Bluelight, Drugs-
forum, ecstasydata.org, Erowid, Eve&Rave, Reddit and 
The Vespiary.
Additionally, the scientific networks of the authors were 
contacted to obtain information.
(4) CAS RNs are especially useful for conducting searches for online 
vendors of any substance because it overcomes nomenclatural and 
language limitations.
RISK ASSESSMENTS | Acryloylfentanyl Annex 1: Technical report
20/50
Section A. Physical, chemical, 
pharmaceutical and pharmacological 
information
A1. Physical, chemical, and pharmaceutical 
information
A1.1. Physical and chemical description
Chemical description and names
N-(1-Phenethylpiperidin-4-yl)-N-phenylacrylamide 
(acryloylfentanyl) is an acrylamide derivative of 
4-anilinopiperidine and is an unsaturated analogue of 
fentanyl, which is a propionamide (Figure 1). 
Acryloylfentanyl contains one basic nitrogen atom in the 
piperidine ring readily forming salts with organic or 
inorganic acids. All the fentanyl derivatives have in 
common an aryl group linked to an 
4-N-acetylanilinopiperidine.
Acryloylfentanyl is a close structural relative of 
fentanyl (5,6) which is a fast but short-acting synthetic 
opioid that has been widely used in clinical practice as 
an adjunct to general anaesthesia during surgery and for 
pain management. 
Acryloylfentanyl is also structurally related to acetylfentanyl, 
which was the subject of an EMCDDA–Europol Joint 
Report in 2015 following more than 30 deaths over a short 
period of time (EMCDDA & Europol, 2015).
Acryloylfentanyl is known from the scientific literature only. 
Pharmacologically, acryloylfentanyl is an opioid.
Fentanyl and congeners were first disclosed in patents 
by the Belgian company Research Laboratorium Dr. 
C. Janssen in the early 1960s (Janssen and Gardocki, 
1964; Janssen, 1965; see also Janssen, 1962). Neither 
acryloylfentanyl nor any other unsaturated amides were 
claimed in the original patents. The synthesis and 
antinociceptive activity of acryloylfentanyl were first 
described in 1981 (Zhu et al., 1981).
Fentanyl analogues first emerged on the illicit drug 
market in the United States of America in 1979; in fact, 
the term ‘designer drugs’ was specifically coined for 
these substances which at the time were not controlled 
(5) http://www.emcdda.europe.eu/publications/drug-profiles/fentanyl
(6) Fentanyl is included in Schedule I of the 1961 United Nations Single 
Convention on Narcotic Drugs of 1961 as amended by the 1972 
Protocol.
under drug legislation (Henderson, 1988) (7). While 
acryloylfentanyl was not detected, its side-chain 
methylated homologue, that is α-methyl-
acryloylfentanyl (8), was identified in samples along with 
α-methyl-acetylfentanyl (Anonymous, 1983; Clark and 
Nelson, 1984; Cooper et al., 1986).
Fourteen fentanyl derivatives are controlled under the 
1961 United Nations Single Convention on Narcotic 




para-fluorofentanyl, thiofentanyl and acetylfentanyl. 
Alfentanil, fentanyl, sufentanil and remifentanil are 
controlled under Schedule I. The controls on 
acetylfentanyl entered into force on 18 May 2016.
Names and other identifiers
Systematic International Union of Pure and Applied 
Chemistry (IUPAC) name: N-phenyl-N-[1-(2-phenylethyl)
piperidin-4-yl]prop-2-enamide




N-phenylacrylamide, enfentanyl (Essawi, 1998).
Commonly used names: acryloylfentanyl or acrylfentanyl
Chemical Abstract Service Registry Numbers 
(CAS RNs) (9,10)
  82003-75-6 free amine  
  79279-03-1  hydrochloride salt
(7) Of note is that Henderson coined the term specifically to convey a 
number of novel characteristics related to the appearance of the 
fentanils on the drug market: ‘“I am probably going to be haunted by 
that until the day I die,” he says. “It sounds like I am trivializing it, but I 
am not. We were getting samples that ranged from a pure white 
powder sold as China White to an off-white powder to a dark brown 
material that looked like Mexican Brown heroin. We got samples that 
were cut with heroin, and I wondered why someone would do that. It 
turns out that can help an addict get on a methadone program. The 
entire packaging and marketing concept to me was a designer 
phenomenon. Additionally, you could literally design the potency and 
duration of action into the molecule”’ (Baum, 1985).
(8) Its names: N-phenyl-N-[1(1-phenylpropan-2-yl)piperidin-4-yl]
prop-2-enamide, N-phenyl-1-(1-phenylpropan-2-yl)acrylamide, 
N-[1-methyl,2-phenylethyl)-4-piperidyl]acrylanilide, or 〈-methyl-
acrylfentanyl; The CAS RN is unknown. Note: in the widely used 
Designer Drugs Directory (Valter and Arrizabalaga, 1998) the CAS RN 
79297-03-1 given for acryloyl-〈-methylfentanyl is erroneous: this 
number in fact denotes acryloylfentanyl hydrochloride (see above).
(9) The Chemical Abstract Service Registry Number (CAS RN) is a unique 
numeric identifier assigned by the Chemical Abstract Service Division of 
the American Chemical Society to a specific, single chemical substance.
(10) An internet vendor (http://drugspowerstore.com) gives CAS RN 
21406-26-7 for acrylfentanyl but this number is actually the CAS RN of 
N-phenyl-1-(2-phenylethyl)piperidine-4-amine (also called 4-ANPP in 
short), the precursor of several fentanyl analogues.
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PubChem SID: 144091883 (11)
IUPAC International Chemical Identifier Key 
(InCHI Key) (12): RFQNLMWUIJJEQF-UHFFAOYSA-N
Street names: acryloyl-F, Acr-F, ACF (13)
Identification and analytical profile
Acryloylfentanyl appears to be mentioned first on a 
Swiss website on 20 January 2014 (Eve&Rave, 
2014) (14). On 5 April, 2016, a picture of a nasal spray 
formulation was posted in Swedish on Twitter (15).
Acryloylfentanyl was first detected as powder in a 
capsule seized in Denmark on 11 May 2016 and 
reported to the EMCDDA on 16 June 2016 (EMCDDA & 
Europol, 2016; Breindahl et al., 2016).
Vendors on the surface web and darknet market places 
have offered acryloylfentanyl as light green or brown to 
light brown powders or as ‘pellets’ (16); the purity is 
usually claimed to be >99 %. In addition, it has also been 
sold on the surface web in Sweden as ready-to-use 
nasal spray solutions; typically these are unlabelled.
Seizures and collected samples reported to the 
EMCDDA and Europol have confirmed the presence of 
(11) https://pubchem.ncbi.nlm.nih.gov/substance/144091883 (created 
15 September 2012)
(12) InChI Key is a unique, non-proprietary stuctural identifier of chemical 
substances useful in electronic sources.
(13) Not to be confused with ‘AF’, which is one of the street names for 
acetylfentanyl (EMCDDA & Europol, 2015).
(14) http://www.eve-rave.ch/Forum/viewtopic.php?f=101&t=34203 
(Accessed: 8 October, 2016)
(15) https://twitter.com/nark80ka/status/717349201726857216 
(Accessed: 8 October, 2016)
(16) Vendors of new psychoactive substances typically used the term 
‘pellets’ rather than ‘tablets’ to describe such dosage forms as an 
apparent attempt to avoid scrutiny by regulatory agencies, including 
medicine regulatory agencies.
acryloylfentanyl in powders, liquids (often as nasal 
sprays), and tablets.
Similar to other fentanils, acryloylfentanyl may be diluted 
with sugars (dextrose, glucose, inositol, lactose, 
mannitol, or sucrose), and common cutting agents (17). 
Some of the powder seizures reported by Estonia 
(Section C) were reported to contain ‘sugars’; no further 
details are available of these samples. A seizure of 
powder in a capsule reported by Denmark was reported 
to contain ‘no lactose or other dilution agents’ (EMCDDA 
& Europol, 2016; Breindahl et al., 2016).
The nasal spray solutions sold on the internet in Sweden 
claim to contain 20 mg acryloylfentanyl per 10 ml 
solution (18); quantification of acryloylfentanyl in nasal 
sprays in samples obtained from the Swedish drug 
market have found 20 mg (Helander, personal 
communication, October 2016).
Latvia reported three small seizures of acryloylfentanyl 
that also contained carfentanil and heroin (no 
quantification of the substances were reported).
Physical description 
Melting point: hydrochloride (HCl) salt: 259–260°C (Zhu 
et al., 1981); 252–258°C with decomposition (Maryanoff 
et al., 1982); 191–194°C (Essawi, 1999); free amine: 
101–103°C (Essawi, 1999).
(17) Early studies reported that the concentrations of some extremely 
potent ’designer fentanils’ in ‘China White’ powders did not typically 
exceed 1 % (Henderson et al., 1990; Henderson, 1991). It was also 
found that the fentanils were uniformly distributed within a single 
sample but their concentration varied up to 300-fold between 
samples; the accidental overdose was thus attributed to the large 
intersample variability rather than to the ‘clumping’ of the drug within 
a sample (Henderson et al., 1990).
(18) https://www.flashback.org/t2671134937 (Accessed: 8 October 2016)
FIGURE 1:  
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There are no solubility data on acryloylfentanyl or its 
hydrochloride salt; due to its close similarity to fentanyl, 
the free base is expected to be sparingly soluble in 
water; the hydrochloride and citrate salt are expected to 
have improved aqueous solubility.
Relevant data for fentanyl: at ambient temperature, 
fentanyl base is poorly soluble in water (0.032 mg per ml 
at pH = 5.9) (Prodduturi et al., 2009) yet intravenous 
injection of one millilitre of such a solution may have 
some psychoactivity (see Gorodetzky and Martin, 1965). 
The solubility of the citrate salt of fentanyl in water is 
~25 mg/ml; in ethanol it is 7.1 mg/ml (Moffat et al., 2011).
Though no experimental data are available, 
acryloylfentanyl, being a close structural analogue of 
fentanyl, is highly lipophilic as indicated by their 
comparable calculated LogP values (19,20).
Chemical stability and typical reactions
Due to its high lipophilicity, carry-over of traces of 
acryloylfentanyl during sample handling and analysis 
can be problematic (see Degg, 2014).
Analytical profile
The ultraviolet and visible spectrum of acryloylfentanyl 
has not been reported.
Fourier Transform Infrared spectrum of the HCl salt (21) 
(diamond ATR attachment)
407, 444, 469, 507, 545, 604, 640, 677, 706, 742, 793, 
954, 974, 982, 1031, 1046, 1089, 1141, 1164, 1266, 
1317, 1340, 1366, 1388, 1411, 1452, 1479, 1494, 1593, 
1614, 1649, 2403, 2453, 2936 and 3045 cm-1 (Slovenian 
National Forensic Laboratory, 2016; see also Breindahl 
et al., 2016) 
Fourier Transform Infrared spectrum of the base form
675, 704, 747, 797, 967, 984, 1028, 1067, 1073, 1121, 
1136, 1242, 1262, 1309, 1325, 1354, 1376, 1410,1452, 
1495, 1594, 1618, 1654, 2767, 2805, 2948, 3028 
and 3061 cm-1 (Slovenian National Forensic Laboratory, 
2016) 
(19) LogP is logarithmic measure of the lipophilicity of a compound by its 
partition coefficient between an apolar solvent (usually 1-octanol) and 
an aqueous buffer.
(20) The respective calculated LogP values for acryloylfentanyl and fentanyl 
are 4.13 and 3.89 (ACD/ChemSketch 2015 release version, Advanced 
Chemistry Development Inc., Toronto, Canada). The respective LogP 
values calculated by StarDrop version 6.3.1 software (Optibrium Ltd, 
Cambridge, UK) for acryloylfentanyl and fentanyl are 3.61 and 3.89. 
The measured LogP value for fentanyl is 4.05 (Hansch et al., 1995).
(21) Spectrum was taken of the crude sample as received.
Nuclear magnetic resonance (NMR) spectra
1H-NMR in CD
3
OD (400 MHz): δ 1.86 (qd, J = 8, 4 Hz, 
CH
2
), 2.19–2.26 (m, 2H, CH
2
), 3.05–3.10 (m, 2H, PhCH
2
), 
3.22–3.29 (m, 2H, CH
2





), 4.90 (tt, J = 12, 4 Hz, 1H, N-CH),# 
5.59 (dd, J = 10.5, 2 Hz, 1H, -CH=CH ’), 5.91 (dd, J = 17, 
10.5 Hz, 1H, CH
2
=CH), 6.31 (dd, J = 17, 2 Hz, 1H, 
-CH=CH), 7.27–7.39 (m, 7H, Ph), 7.52–7.60 (m, 3H; Ph), 
12.75 (bs, N+) (Breindahl et al., 2016; see also Essawi, 
1999; Slovenian National Forensic Laboratory, 2106). 
#Overlapping with signal from the NMR solvent.
13C-NMR in DMSO (125 MHz): δ 27.6, 29.9, 50.0, 51.3, 
56.9, 127.2, 128.1, 129.1, 129.1, 129.2, 129.5, 130.0, 
130.9, 137.6, 137.9 and 164.7 (Slovenian National 
Forensic Laboratory, 2106; see also Breindahl et al., 
2016).
DEPT and two-dimensional (COSY and HSQC) NMR 
spectra are also available (Breindahl et al., 2016).
Chromatographic analyses coupled with mass 
spectrometry (GC-MS)
Electron impact (EI) mass spectrum of acryloylfentanyl 
(characteristic fragments): m/z 243 (base peak), 200, 
189, 146, 105 and 55 (Breindahl et al., 2016; see also 
Essawi, 1999; Slovenian National Forensic Laboratory, 
2106).
Quadrupole time-of-flight (QTOF) and matrix-assisted 
laser desorption/ionization Orbitrap (MALDI/Orbitrap) 
mass spectrometric analyses of acryloylfentanyl have 
also been described (Breindahl et al., 2016).
A highly sensitive capillary electrophoresis-electrospray-
tandem mass spectrometry method recently developed 
for the trace level analysis of fentanils (Rittgen et al., 
2012) could be applicable for acryloylfentanyl.
Immunoassay
Similar to fentanyl, it is expected that acryloylfentanyl 
does not give a positive response to immunoassay tests 
developed for morphine-type opioids. There is no data 
on whether immunoassays developed for fentanyl or 
other fentanils would give positive responses to 
acryloylfentanyl. Acryloylfentanyl did not show cross-
reactivity with the immunoassay panel 
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ABC-multi-10 (Simoco Diagnostic, Hillerød, Denmark), 
which includes MDMA (Breindahl et al., 2016) (22). 
Presumptive colour tests
There is no information on the reaction of 
acryloylfentanyl to presumptive colour tests.
Methods and chemical precursors used for 
the manufacture 
Information on the chemical precursors and the 
synthetic methods employed for acryloylfentanyl 
detected on the drug market within the European Union 
is limited to information from one seizure (discussed 
below).
Detailed information available with regards to route-
specific by-products produced during the synthesis 
of acryloylfentanyl is currently not available.
Synthesis
The manufacture of acryloylfentanyl relies on precursors 
and synthetic methods similar to those used for the 
manufacture of pharmaceutical fentanyl. Accordingly, 
methods developed for the multistep synthesis of 
fentanyl are applicable to acryloylfentanyl but use a 
different acylating agent in the final acylation step. 
Due to the therapeutic importance of fentanyl, several 
routes have been developed for its synthesis (see, for 
example, Zee et al., 1980; Casy and Huckstep, 1988; 
Gupta et al., 2005). These methods have been critically 
reviewed (Soine, 1986; Carroll and Brine, 1989; Hsu and 
Banks, 1992; Fritschi and Klein, 1995; Yadav et al., 2010; 
Vardanyan and Hruby, 2014). Most of these synthetic 
procedures are straightforward, use common laboratory 
equipment and precursors, and detailed recipes are 
available on the internet (23). 
While only basic knowledge of synthetic chemistry is 
required, due to the high potency of fentanils there is a 
serious risk of severe poisoning following accidental 
exposure during its manufacture. Extreme care must be 
taken when carrying out the final synthetic step as well 
(22) Breindahl et al. (2016) mention that the initial tests carried out at a 
psychiatric ward at a Danish hospital with a sample of the unpurified 
powder indicated positive reaction for MDMA, therefore the sample 
was forwarded to further analysis, which then showed that the 
powder contained acryloylfentanyl and triethylamine. It is not known, 
however, that triethylamine would crossreact with an MDMA 
immunoassay or not.
(23) The detailed description of the most common procedure, often called 
the ‘Siegfried method’, is readily available on the Internet (see, for 
example, http://opioids.com/fentanyl/synthesis.html).
as when purifying and handling the substance (24). 
Likewise, accidental exposure to fentanils — such as 
skin contact, inhalation, or ingestion — pose a serious 
risk of poisoning to the public, law enforcement, 
emergency personnel, as well as medical and forensic 
laboratory personnel. In addition to exercising extreme 
caution when handling materials suspected to contain 
fentanils, working environments and personnel should 
be equipped with appropriate protective equipment. In 
addition, the antidote naloxone should be readily 
available to personnel in sufficient quantities; training in 
resuscitation and naloxone administration should also 
be available (CDC, 2017; CDC, 2013; DEA, 2016).
The two published synthetic methods of acryloylfentanyl 
describe the acylation of the common precursor 
4-ANPP (25,26) with acryloyl chloride (27) (Zhu et al., 1981; 
Maryanoff et al., 1982) or 3-chloropropionyl chloride (28) 
(Essawi, 1998, 1999) as depicted in Figure 2.
Acylation of 4-ANPP with acryloyl chloride in the 
presence of a base, such as sodium carbonate, in an 
inert solvent affords directly acryloylfentanyl (top of 
Figure 2). In the similar synthesis of the acroyl analogue 
of the analgesic 2,5-dimethylfentanyl (phenaridine, also 
spelled as fenaridin) a 1.5 molar equivalent triethylamine 
was used (Vartanyan et al., 1989). The use of an 
additional base is, however, not necessary since the 
basic piperidine moiety present in the substance may 
serve as an acid scavenger.
Alternatively, acylation with 3-chloropropionyl chloride in 
the presence of an excess of a base, such as 
triethylamine, results in the simultaneous elimination of 
hydrochloride to provide the desired acryloyl product 
(bottom of Figure 2). This method has been used for the 
(24) Self-educated clandestine chemists commented on the risk while 
discussing the synthesis of fentanyl and its potent 3-methyl and 
〈-methyl homologues (verbatim, all in bold!). “A synthesis as 
dangerous as this one should not be written in a way that novices 
think it is a very easy drug to synthesize cheaply, and earn a great 
money on. The truth is that the odds are AGAINST them with a potent 
opioid like this – a lot of them trying WILL get hurt, or in the best case 
scenario completely fails the reaction so that they doesn’t ingest 
highly potent respiratory depressant, probably a lethal lose is present 
in the fume hood the reaction is taking place in, or dispersed into the 
room if the hood is dysfunctional or non-existant.” (comment was 
posted on 7 May, 2002); available at: https://the-hive.archive.erowid.
org/forum/showflat.pl?Cat=&Number=260275 (Accessed: 
6 October 2016)
(25) CAS RN: 21409-26-7. For analytical characterisation, see http://
www.swgdrug.org/Monographs/4ANPP.pdf. Note that 
1-(2-phenylethyl)piperidin-4-one, or NPP (CAS RN: 39742-60-4), a 
precursor to 4-ANPP, is also used for the manufacture of the 
bronchodilatory medicine fenspiride.
(26) The synthesis of 4-ANPP from phenethylamine and ethyl (or methyl) 
acrylate is well documented (Beckett et al., 1959; Jończyk et al., 1978; 
Maryanoff et al., 1982). For another route, see Valdez et al. (2014).
(27) IUPAC name: prop-2-enoyl chloride; CAS RN: 814-68-6; European 
Community (EC) Number: 212-399-0
(28) IUPAP Name: 3-chloropropanoyl chloride, CAS RN: 625-36-5; 
European Community (EC) Number: 210-890-4
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synthesis of another series of acryloyl fentanyl 
analogues (Girón et al., 2002).
A powder sample in a capsule seized in Denmark was 
shown to consist of mainly acryloylfentanyl and a 
substantial amount of triethylamine hydrochloride 
(27 %) which indicates the use of triethylamine base as 
an acid scavenger during manufacture of the drug. In 
addition to triethylamine, 4-ANPP was also detected as a 
minor contaminant in the sample but no quantification 
was made (EMCDDA & Europol, 2016; Breindahl et al., 
2016).
Other acylation methods that use an activated ester of 
acrylic acid can also be used.
An alternative, potential synthetic route for the 
manufacture of acryloylfentanyl would involve the 
alkylation of N-phenyl-N-(piperidin-4-yl)acrylamide (29) 
with a phenethyl halide in the presence of sodium 
(bi)carbonate or another base (30).
None of the synthetic precursors mentioned above are 
included in Table I or Table II of the United Nations 
Convention against Traffic in Narcotic Drugs and 
Psychotropic Substances, 1988. However, a proposal in 
(29) Systematic name: N-phenyl-N-(piperidin-4-yl)prop-2-enamide
(30) This method was described for fentanyl and a series of its analogues 
(Janssen, 1965; reviewed by Hsu, 1992).
June 2010, the USA Drug Enforcement Administration 
placed 4-ANPP (named ANPP in the regulation) into 
Schedule II of the Controlled Substances Act (DoJ-DEA, 
2010). 
It should be mentioned that, at least in theory, 
acryloylfentanyl may serve as a precursor to the 
internationally controlled fentanyl by saturating the 
double bond of the acrylamide moiety using catalytic 
hydrogenation (for a similar example, see Huckle et al., 
1972).
In summary, the synthesis of acryloylfentanyl has been 
described in the literature. Other routes developed for 
the production of fentanyl may also be used for the 
manufacture of acryloylfentanyl. Information on the 
method(s) used for the production of acryloylfentanyl 
available on the drug market is limited to the detection of 
4-ANPP and triethylamine hydrochloride that were 
detected in one seizure (EMCDDA & Europol, 2016; 
Breindahl et al., 2016).
Typical impurities encountered in seized and 
collected samples
Data on the impurities encountered in samples 
containing acryloylfentanyl is limited to the first seizure 
reported to the EMCDDA. In this seizure, 4-ANPP and 
triethylamine hydrochloride, believed to be used in the 
synthesis of acryloylfentanyl, were detected (EMCDDA 
& Europol, 2016; Breindahl et al., 2016).
FIGURE 2  
Synthesis of acryloylfentanyl from N-phenyl-1-(2-phenylethyl)piperidin-4-amine (4-ANPP) and acryloyl chloride 
(Zhu et al., 1981) (top) or 3-chloropropionyl chloride (Essawi, 1998, 1999) (bottom; the intermediate 
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A1.2. Physical/pharmaceutical form 
Data from seizures and collected samples reported to 
the EMCDDA have noted that acryloylfentanyl has 
typically been detected in powders, liquids or in tablets. 
Typically the liquids have been seized as unlabelled 
ready-to-use nasal sprays. In one case a capsule was 
seized that contained a powder (Section C) (EMCDDA & 
Europol, 2016; Breindahl et al., 2016).
A1.3. Route of administration and dosage 
Acryloylfentanyl can be administered orally as a powder 
(including in capsules), as tablets, or as a solution; it can 
also be administered intranasally or sublingually via a 
spray; inhaled by vaporising e-liquid solutions (‘vaping’); 
inhaled by smoking or vaporising the ‘free base’; 
injected; and, applied transdermally.
Data reported to the EMCDDA regarding acute 
intoxications suspected to involve acryloylfentanyl 
(Section D1.2) shows that intranasal administration, 
presumably using a nasal spray, was the most common 
route of administration (59 %; 10 out of 17 non-fatal 
intoxications for which a route of administration was 
reported); while the most common physical form used 
were ‘nasal solutions’ (68 %; 13 out of 19 cases for 
which a physical form was reported). Less commonly, 
snorting of powder or crushed tablets, oral consumption 
of tablets, and injection of a ‘nasal solution’ were also 
reported. 
In one of the seizures reported to the EMCDDA 
acryloylfentanyl was detected in a liquid recovered from 
inside a syringe.
Discussions on user websites include the descriptions of 
homemade preparations for vaping acryloylfentanyl in 
an e-cigarette (31). In one case, a user describes the 
preparation of a ‘homemade, rum-flavoured e-liquid 
prepared from 65 % PG [propylene glycol] and 35 % VG 
[vegetable glycerol]’ to provide an ‘acrylfent’ solution of 
24 mg/ml for vaping. In addition, an experience with a 
homemade transdermal patch preparation has also 
been discussed (32).
Dosage and dosage regimens
Limited information is available regarding the dose and 
the dose regimens of acryloylfentanyl. From the limited 





dosages administered by users. While a range of doses 
have been reported, these appear to differ depending on 
factors such as the route of administration, the tolerance 
of the users, the use of other drugs, and the desired 
effects. Given the difficulties of collecting such data 
accurately the information below should be used with 
caution.
Data reported to the EMCDDA regarding acute 
intoxications suspected to involve acryloylfentanyl 
indicate that a range of doses may be used, with 
re-dosing during the course of a day reported in some 
cases. This includes two cases that reported using 
‘20 mg’ intranasally per day and who appeared to have 
tolerance to the substance following use over the 
preceding months.
Analysis of the concentration of acryloylfentanyl in nasal 
spray solutions from Sweden suggests that a 10 mL 
spray bottle typically contains 20 mg of the substance 
(Helander, personal communication, October 2016). 
It should be noted that the preparation of solutions 
containing milligram amounts of substance is inherently 
prone to risks in weighing and dilution and therefore 
solutions with higher (or lower) concentrations can be 
mistakenly prepared and/or sold. 
Some additional information on dosage is provided on 
user websites. As already highlighted, the assessment of 
such reports is problematic because the purity, amount 
and/or composition of the substance ingested are 
typically not known by the user. Moreover, the actual 
composition of the substance may differ over time and 
different geographical areas. The difficulty in assessing a 
‘typical’ acryloylfentanyl dose from such websites is 
further compounded by the fact that miligrams and 
micrograms are sometimes used interchangeably.
For nasal sprays, doses of 0.0027 mg to 0.2 mg were 
reported on user websites. Some of these reports (33) 
suggested that oral doses of 5–12.5 µg of 
acryloylfentanyl may produce ‘light’ effects, and doses of 
25–47.5 µg may produce ‘strong’ effects. The source of 
these figures is unknown. 
(33) http://drugs.tripsit.me/acryl-fentanyl#basic
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There has been one study published in the scientific 
literature on the opioid receptor binding of 
acryloylfentanyl. Maryanoff et al. (1982) determined the 
binding affinities of a series of compounds, including 
acryloylfentanyl, designed as potential covalent receptor 
affinity labels using a rat brain preparation and tritiated 
naloxone or naltrexone as competing opioid receptor 
ligands (34). Morphine, fentanyl and the highly potent 
fentanyl analogue (+)-3-methylfentanyl were used as 
comparative standards.
As seen in Table 1, the IC
50
 values (35) obtained for 
fentanyl and acryloylfentanyl were similar; morphine was 
somewhat less effective in inhibiting the binding of 
radiolabeled receptor antagonists.
The results of this study indicate that the opioid receptor 
affinity of acryloylfentanyl is similar to that of fentanyl 
and somewhat higher than that of morphine, at least in 
this particular rat brain preparation. Laboratory 
experiments failed to find evidence for irreversible 
binding of acryloylfentanyl to opioid receptors 
(Section D1.1).
A search in the PubChem Substance database for 
biological activity of acryloylfentanyl (36) identified 
28 test results deposited, yet the substance was found 
inactive in all assays that included a range of non-opioid 
related targets (NCBI PubChem, 2012).
(34) Naloxone and naltrexone are potent antagonists (though may behave 
as inverse agonists also) of opioid receptors. Both have preference for 
μ opioid receptors, which are implicated in analgesia and withdrawal, 
as well as in respiratory depression and lethality in overdose cases. 
(35) The binding constant IC
50
 (half maximal inhibitory concentration) 
refers to the molar concentration of a drug that displaces 50 % of a 
well-characterised ligand from the receptor preparation in vitro.
(36) Available at: https://pubchem.ncbi.nlm.nih.gov/
substance/144091883 (accessed: 6 October 2016).
Animal studies
There have been two studies investigating the 
antinociceptive activity of acryloylfentanyl in the mouse 
(Zhu et al., 1981; Essawi, 1998, 1999).
The first publication mentioning acryloylfentanyl 
describes an extensive structure–activity relationship 
study involving 22 fentanyl analogues, with morphine 
and fentanyl as comparative standards (Zhu et al., 1981). 
The antinociceptive activities of morphine, fentanyl and 
acryloylfentanyl in mice upon intraperitoneal 
administration are shown in Table 2.
As Table 2 indicates, in this mouse model of analgesia, 
acryloylfentanyl is about 170-times more potent as an 
antinociceptive agent than morphine, though somewhat 
less potent than fentanyl.
Essawi studied five fentanyl analogues, including 
acryloylfentanyl, as potential receptor affinity labels and 
antinociceptive agents in the mouse using the hot-plate 
assay; morphine and fentanyl were used as comparative 
standards (Essawi, 1998, 1999) (37). Upon 
intraperitoneal administration at doses below 1 mg/kg, 
acryloylfentanyl was a more potent antinociceptive 
agent than fentanyl. While the effect of fentanyl at 0.1, 
0.2 and 0.5 mg/kg dropped considerably at 60–
70 minutes and became insignificant at 90–100 minutes 
after treatment, it was reported that at comparable 
doses, acryloylfentanyl maintained considerable 
analgesia at 90 and 120 minutes after administration. In 
its duration of action, the time-response profile of 
acryloylfentanyl resembled more closely that of 
morphine (20 mg/kg) than that of fentanyl. Remarkably, 
at 6.8 mg/kg and 17 mg/kg doses the antinociceptive 
effect of acryloylfentanyl was sustained up to 4.5 hours 
without signs of opioid toxicity. At the 25 mg/kg dose, it 
was reported that the motor activity was inhibited, but 
that the animals were not cataleptic and they returned to 
(37) Fentanyl citrate, morphine sulfate were dissolved in water while 
aqueous solutions of the fentanyl analogues were prepared from the 
free base in the presence of equimolar citric acid. Appropriate doses 
of all test substance solutions were injected intraperitoneally  
at 10 ml/kg.
TABLE 1  
Opioid receptor binding data for acryloylfentanyl, morphine, fentanyl and (+)-3-methylfentanyl (Maryanoff et al. 
1982). The receptor affinity is expressed by IC
50
 values representing the concentration required for displacement of 
50 % of tritiated naloxone or naltrexone radioligands in a competition assay using rat brain homogenates.
Compound IC
50







RISK ASSESSMENTS | Acryloylfentanyl Annex 1: Technical report
27/50
continuous circling behaviour 3.5 hours after treatment. 
However, following administration of a dose of 50 mg/kg, 
convulsions developed after 1 hour and 60 % lethality 
was observed from apparent respiratory depression.
Pre-administration by 30 minutes of 2 mg/kg naloxone 
blocked the antinociceptive effect of 0.85 mg/kg 
acryloylfentanyl for about 40 minutes, after which this 
antagonist effect disappeared and analgesia and other 
morphine-like effects could be noted for about 
50 minutes. A similar transient antagonist effect was 
observed when naloxone (2 mg/kg) was administered 
40 minutes after acryloylfentanyl treatment 
(0.85 mg/kg): the reversal of the antinociceptive effect 
lasted for 70 minutes, and then antinociception returned 
to the same level as before naloxone administration. The 
author of the study concluded that acryloylfentanyl ‘has 
a mode of interaction with µ−receptors different from 
morphine’ (38).
In summary:
 § Studies in vitro and in mice establish acryloylfentanyl 
as a potent and long-lasting antinociceptive agent 
acting on the opioid system.
 § The antinociceptive activity of acryloylfentanyl is 
blocked by the opioid antagonist naloxone though this 
protective effect is transient.
 § The acute toxicity of acryloylfentanyl has not been 
determined but based on observations during 
a mouse-study, it appears to be similar to that of 
fentanyl.
(38) The proposal by Essawi (Essawi, 1999) that the observed temporary 
antidotal effect of naloxone was due to noncompetitive binding of the 
morphine analogue naloxone to an allosterical site whereby inhibiting 
the pharmacological response of covalently bound arcyloylfentanyl 
until naloxone was eliminated appears to be in conflict with earlier 
research indicating the lack of covalent binding of acryloylfentanyl to 
opioid receptors in vitro (Maryanoff et al., 1982). A possible 
explanation for the discrepancy could be that Essawi carried out the 
mouse experiments in vivo while Maryanoff et al. (1982) used rat brain 
receptor preparations in vitro.
Pharmacokinetics
Due to its lipophilicity (Section A.1.1.), acryloylfentanyl, 
like fentanyl, is expected to readily cross the blood–
brain barrier and also diffuse into fat and other tissues, 
i.e., it is likely to have a large volume of distribution.
There appears to be no preclinical or human clinical 
study on the pharmacokinetics, including metabolism, of 
acryloylfentanyl. Nevertheless, the pharmacokinetics 
and the metabolic pathway of acryloylfentanyl are 
expected to be similar to that of fentanyl (McClain et al., 
1980; Goromaru et al., 1984; Guitton et al., 1997; 
DePriest et al., 2015) or acetylfentanyl (Patton et al., 
2014; Melent’tev et al., 2015; Poklis et al., 2015).
The primary route in fentanyl metabolism is oxidative 
N-dealkylation which is catalysed by cytochrome P450 
(CYP450) enzymes and leads to the biologically inactive 
desphenethyl metabolite of fentanyl, usually called 
‘norfentanyl’ (39) (Labroo et al., 1997; see also Goromaru 
et al., 1984; Higashikawa and Suzuki, 2008a).
It is expected that one of the main metabolites present 
in biological matrices is the ‘desphenethyl’ derivative of 
acryloylfentanyl, that is ‘acryloyl norfentanyl’ (40). Amide 
hydrolysis (deacylation) is a minor pathway for fentanyl 
and probably an insignificant biotransformation for the 
acryloyl analogue. Terminal hydroxylation of the acyl 
chain, which is also a minor biotransformation step for 
fentanyl in humans, produces what is often called 
‘hydroxyfentanyl’ (41) but such a hydroxylation cannot 
take place in case of acryloylfentanyl.
There is some information on the biological activity of 
two potential metabolites of acryloylfentanyl. An study 
assessing the opioid-like activity of several fentanyl 
metabolites in the guinea pig ileum assay, found that 
(39) Systematic name: N-phenyl-N-(piperidin-4-yl)propanamide. Molecular 
weight: 232.32.
(40) Systematic name: N-phenyl-N-(piperidin-4-yl)prop-2-enamide. 
Molecular weight: 230.30.
(41) Systematic name of this metabolite: 3-hydroxy-N-phenyl-N-[1-(2-
phenylethyl)piperidin-4-yl]propanamide.
TABLE 2  
Antinociceptive activity of morphine, fentanyl and acryloylfentanyl in mice upon intraperitoneal administration (Zhu 




 () (mg/kg) Potency ratio to morphine Potency ratio to fentanyl
Morphine 13.9 1 0.0045
Fentanyl 0.062 224 1
Acryloylfentanyl 0.082 169.5 0.76
RISK ASSESSMENTS | Acryloylfentanyl Annex 1: Technical report
28/50
4-ANPP and 4-anilinopiperidine (42) were less potent 
than fentanyl by 4 to 5 orders of magnitude (Schneider 
and Brune, 1986). Compared to morphine, these two 
anilines were also less potent by 3 to 4 orders of 
magnitude. The only metabolite showing significant 
activity in this study was a phenolic derivative 
hydroxylated at the 4-position of the phenylethyl moiety 
of fentanyl (43) (Figure 3), the activity of which was found 
to lie between morphine and pethidine. This implies that 
the corresponding phenolic metabolite of 
acryloylfentanyl (44), if formed, may have some level of 
opioid activity and thus may contribute to the biological, 
including toxicological, properties of the parent 
substance.
No information was found in the published literature 
regarding two other potential metabolites of 
(42) Systematic name: N-phenylpiperidine-4-amine.
(43) Of the potential mono- and dihydroxylated metabolites only this 
substance, that is N-{1-[2-(4-hydroxyphenyl)ethyl]piperidin-4-yl}-N-
phenylpropionamide, was tested.
(44) Systematic name: N-{1-[2-(4-hydroxyphenyl)ethyl]piperidin-4-yl}-N-
phenylprop-2-enamide
acryloylfentanyl: i) the desphenethyl derivative of 
acryloylfentanyl and ii) nor-acryloylfentanyl (45).
Inter-individual genetic variability in metabolising 
enzymes
For fentanyl, oxidative dealkylation by hepatic 
CYP450 3A4 and by CYP450 3A5 isoenzymes has been 
demonstrated (Labroo et al., 1997; Jin et al., 2005; see 
also Guitton et al., 1997). The wide variation of the 
expression of the genes coding for these CYP450 3A 
isoenzymes among populations is of clinical significance, 
but the toxicological consequence of such 
polymorphisms has not been investigated in fentanyl 
poisonings.
Interactions with other substances, medicines, and 
other forms of interactions
Should acryloylfentanyl undergo oxidative dealkylation 
by hepatic CYP450 3A4 and by CYP450 3A5 
isoenzymes then the use of this substance with 
(45) Exact structure search was done in SciFinder®. 
FIGURE 3  
Some potential human metabolites of acryloylfentanyl. Note that due to incomplete acylation during manufacture, 
4-ANPP could be present in the consumed products thus its detection in biological matrices might not be indicative 
of metabolism.
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inhibitors of these isoenzymes, such as ketoconazole, 
clarithromycin, indinavir, itraconazole, nefazodone, 
ritonavir, saquinavir (all strong CYP3A inhibitors), 
erythromycin, fluconazole, grapefruit juice, verapamil (all 
moderate CYP3A inhibitors) (EMA, 2016; EMA, 2017; 
McCance-Katz, et al., 2010) may result in increased 
plasma concentration of acryloylfentanyl which could be 
toxicologically significant. Overall, this could increase 
the risk of poisoning including potentially fatal 
respiratory depression.
The concomitant use of other central nervous system 
(CNS) depressants with opioid analgesics, including 
other opioids, sedatives/hypnotics (such as the 
benzodiazepines and the z-drugs), ethanol, 
gabapentinoids (pregabalin and gabapentin), 
tranquillisers, sedating anti-histamines, and skeletal 
muscle relaxants may produce additive depressant 
effects (EMA, 2016; EMA, 2017). Of note in this respect 
is that polydrug use was common in the deaths reported 
to the EMCDDA, including the use of other CNS 
depressants such as benzodiazepines, pregabalin, 
gabapentin and ethanol (Section D).
The use of fentanyl with serotoninergic agents, such as 
Selective Serotonin Re-uptake Inhibitors (SSRIs) (the 
most commonly prescribed antidepressants) or 
Serotonin Norepinephrine Re-uptake Inhibitors (SNRIs) 
or Monoamine Oxidase Inhibitors (MAOIs) has been 
associated with serotonin syndrome, a potentially 
life-threatening condition (EMA, 2016; EMA, 2017). This 
association is likely to extend to illicit drugs which act on 
the serotonergic system. It is not known if this 
association is also seen with acryloylfentanyl.
Severe and unpredictable potentiation by MAOI 
inhibitors has been reported with opioid analgesics 
(EMA, 2016; EMA, 2017).
Similar to fentanyl, the use of partial opioid agonists/
antagonists (such as buprenorphine, nalbuphine, 
pentazocine) which have high affinity to opioid receptors 
but relatively low intrinsic activity could partially 
antagonise the effects of acryloylfentanyl and may 
induce withdrawal symptoms in people who are opioid 
dependant (EMA, 2016; EMA, 2017).
Effects on ability to drive and operate machines
No studies of the effects of acryloylfentanyl on the 
ability to drive and operate machines have been 
performed. However, it is well established that opioid 
analgesics, such as fentanyl, impair the mental and 
physical ability required to drive and operate machines. 
This effect is likely to extend to acryloylfentanyl.
A3. Psychological and behavioural effects
Information on the psychological and behavioural 
effects of acryloylfentanyl is limited to serious adverse 
events reported to the EMCDDA and self-reported 
experiences from user websites.
The psychoactivity of acryloylfentanyl is reportedly 
similar to that of other opioids and characterised by 
relaxation and euphoria. Internet forums rarely mention 
side or adverse effects typical of opioids.
For fentanyl, which is structurally very similar to 
acryloylfentanyl, as little as 0.025 to 0.050 mg doses 
given intravenously could produce psychoactive effects 
(or the ‘high’), which are often compared to heroin. For 
example, an early study with ‘postnarcotic addicts’ 
compared the miotic and euphorogenic effects of 
fentanyl and morphine, both administered 
intramuscularly (Gorodetzky and Martin, 1965): fentanyl 
at the 0.8 and 1.6 mg per 70 kg doses was 25 times as 
potent as morphine in constricting pupils but 50 times 
as potent as morphine as measured by opiate symptom 
scores as well as subject and observer ‘liking’ scores; 
the effects of fentanyl gradually diminished after the 
second hour. Morphine, on the other hand, did not show 
such a decrease in effects until after the fourth hour. 
Though human clinical studies are lacking, it may be 
assumed that the opiate-like effects of acryloylfentanyl 
manifest at doses similar to those observed for fentanyl. 
User self-reports posted on internet forums mention 
sub-milligram doses administered by nasal spray as 
being psychoactive.
A4. Legitimate uses of the product
Acryloylfentanyl is used as an analytical reference 
material in clinical and forensic case work/investigations 
as well as scientific research. Analytical reference 
materials are available commercially. There is currently 
no information that suggests acryloylfentanyl may be 
used for other legitimate purposes.
There are no reported uses of acryloylfentanyl as 
a component in industrial, cosmetic or agricultural 
products. In addition, a search of the Registration, 
Evaluation, Authorisation and Restriction of Chemicals 
(REACH) registered substances database hosted by the 
European Chemicals Agency (ECHA) using the CAS 
Registry Number returned no results.
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There is no marketing authorisation (existing, ongoing or 
suspended) for acryloylfentanyl neither in the European 
Union nor in the Member States that responded to the 
request for information from the European Medicines 
Agency which was undertaken as part of the Joint 
Report process (EMCDDA and Europol, 2016).
There is no information to suggest that acryloylfentanyl 
is currently used in the manufacture of a medicinal 
product in the European Union. However, in the absence 
of a database on the synthetic routes of all medicinal 
products it is not possible to confirm whether or not 
acryloylfentanyl is currently used in the manufacture of 
a medicinal product.
Section B. Dependence and abuse 
potential
B1. Animal data
No studies were identified that have investigated the 
dependence and/or abuse potential of acryloylfentanyl 
in animal models.
B2. Human data
No studies were identified that have investigated the 
dependence and/or abuse potential of acryloylfentanyl 
in humans.
The limited information available from user websites 
suggests that some users of acryloylfentanyl report an 
urge to re-dose as well as symptoms suggestive of 
withdrawal.
While no specific data exists for acryloylfentanyl, it is 
well established that opioid analgesics such as fentanyl 
have an abuse liability and can induce tolerance and 
dependence. Research will be required in order to 
determine such effects.
Section C. Prevalence of use
Information from seizures, collected and 
biological samples
Acryloylfentanyl was formally notified on 7 July 2016 by 
the EMCDDA on behalf of the Danish national focal 
point, in accordance with Article 4 of the Council 
Decision. The Reporting Form details a capsule that was 
seized on 11 May 2016 by the Department of Forensic 
Psychiatry of the Aalborg Psychiatric Hospital. The 
identification and analytical characterisation was based 
on a range of analytical techniques GC-MS, high-
resolution mass spectrometry (HR-MS) and NMR. The 
GC-MS analysis showed that the synthetic precursor 
used was 4-ANPP, which can also be used for the 
synthesis of fentanyl. The impurities, triethylamine 
hydrochloride and 4-ANPP were detected (Section A1.1) 
(EMCDDA & Europol, 2016; Breindahl et al., 2016).
Since then, a total of six Member States have reported 
detections of acryloylfentanyl (46) (EMCDDA and 
Europol, 2016).
Information from seizures
A total of five Member States (Denmark, Estonia, Finland, 
Latvia and Sweden) reported seizures (47) of 
acryloylfentanyl to the EMCDDA and/or Europol.
Information reported to the EMCDDA and Europol 
indicates that 162 seizures of acryloylfentanyl have been 
reported by: Denmark (1 seizure), Estonia (61), 
Finland (1), Latvia (17), and Sweden (82). All the 
seizures were made during 2016 and 2017 by Police or 
Customs. Many seizures have been made at street-level.
These seizures included:
 § 84 seizures of powder amounting to 112.667 
g (Estonia, Latvia and Sweden). In Latvia, one of the 
(46) ‘Detections’ is an all-encompassing term and may include seizures 
and/or collected and/or biological samples that are analytically 
confirmed. Seizure means a substance available (seized) through law 
enforcement activities (police, customs, border guards, etc.). 
Collected samples are those that are actively collected by drug 
monitoring systems (such as test purchases) for monitoring and 
research purposes. Biological samples are those from human body 
fluids (urine, blood, etc.) and/or specimens (tissues, hair, etc.) 
(47) Many ‘seizures’ relate to individual case-level data, however, some 
data provided to the EMCDDA are aggregated at the country level. 
Data is drawn from the Joint Report Questionnaires and data 
provided in the bi-annual data gathering (EU EWS progress and final 
reports) and from individual Reporting forms submitted on an ad hoc 
basis.
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seizures was made at a scene of death (48); while an 
additional seizure was made in prison from incoming 
mail (a package with light beige powder which was 
hidden inside a tube for cosmetic cream). Latvia 
reported three small seizures of acryloylfentanyl that 
also contained carfentanil and heroin (no 
quantification of the substances were reported).
 § 50 seizures of liquids, made in Sweden (49) and in 
Latvia (1), amounting to a total of 1 495 mL.
 § 27 seizures of tablets (Sweden and Finland) 
amounting to 896 tablets. This includes one seizure of 
99 blue oval tablets with no logos or markings that 
was seized in Finland.
 § 1 capsule seized in Denmark.
The detected quantities are relatively small; however, 
they should be considered in the context of the high 
potency of acryloylfentanyl.
Information from collected samples
Slovenia reported a sample of light green powder which 
was purchased from an internet vendor. The sample was 
shipped from China and was received in May 2016.
Information from biological samples
A total of 54 detections where acryloylfentanyl was 
analytically confirmed in biological samples were 
reported by three Member States: Denmark (1), 
Estonia (3), and Sweden (50).
These related to:
 § 47 deaths reported by Denmark (1), Estonia (3), and 
Sweden (43).
 § 6 cases from Sweden related to patients undergoing 
drug treatment, persons suspected of having 
consumed drugs, or persons committing minor 
offences, or crimes.
 § 1 case from Sweden of a person suspected of driving 
under the influence of drugs.
Availability, supply, price
Data from seizures, collected samples and acute 
intoxications suspected to involve acryloylfentanyl 
suggests that the substance is sold online, typically as 
a powder and as ready-to-use nasal sprays. 
Acryloylfentanyl is sold as a ‘research chemical’ online 
(48) Latvia reported 1 death where acryloylfentanyl was identified in 
seizure made at the scene of death. However, post-mortem analysis of 
biological samples only detected alcohol.
and is available in small and wholesale amounts. In 
addition, three small seizures of acryloylfentanyl that 
also contained carfentanil and heroin have been 
reported (no quantification of the substances were 
reported). Overall, the available information suggests 
that acryloylfentanyl is produced by chemical 
companies based in China. In February 2017 it was 
announced that acryloylfentanyl will be controlled in 
China as of the 1 March 2017. This control measure may 
deter at least the open manufacture and sale of this 
substance by such chemical companies and which are 
involved in the supply of the substance in Europe.
Availability from Internet vendors
A structured search by the EMCDDA of online vendors 
(49) of acryloylfentanyl on the surface web (50) was 
conducted in October 2016. The search identified nine 
vendors that appeared to be based in, and/or claim to 
have a presence in China (n=6 sites), in Hong Kong (n=1), 
in India (n=1 sites) and in Denmark (n=1). Eight of the 
sites presented information in English and one site in 
Danish.
Three of the sites only provided prices for 
acryloylfentanyl on application, two presented prices as 
‘negotiable’ and one website displayed no information on 
price. In the latter, quantities from 10 g to 1 000 kg were 
on sale, packaged in foil bags, drums or bottles. The 
remaining three sites listed quantities and prices. Briefly:
 § acryloylfentanyl was typically sold as a ‘research 
chemical’;
 § the minimum quantity offered was 25 tablets 
(n=1 sites) with a price of EUR 67 (51);
 § the maximum quantity offered was 500 g (n=1 sites) 
with a price of EUR 7 322;
 § 2 of the websites identified were part of the TOR 
routing system which suggests they were dark web 
marketplaces. In both sites acryloylfentanyl was 
offered as a powder and advertised as a ‘research 
chemical’;
 § 1 website sold acryloylfentanyl as a nasal spray listed 
as 25 mg / 10 mL with a price of EUR 67.
(49) This includes vendors that appear to be consumer-orientated as well 
as vendors, for example on B2B sites, which appear to be 
manufacturers and/or wholesalers. It excludes those selling 
acryloylfentanyl through online classified advertisements, social 
media, and user websites.
(50) The search of online vendors of acryloylfentanyl was performed on 
21/10/2016 using the search strings: ‘buy acryloylfentanyl’ (searches 
in English, Swedish and Danish, including variations in spelling). The 
first 100 results were recorded and the sites reviewed. Each identified 
vendor site was then scored for information on warehouse location, 
quantities and prices, and substance marketing.
(51) Prices listed in DKK were converted to EUR according to Google 
exchange rate from the 25.10.2016 (DKK 1 = EUR 0.13). 
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In addition the ‘Opiates’ section of the darknet 
marketplace Valhalla contained at least one vendor who 
offered acryloylfentanyl hydrochloride: the respective 
prices for 100 g, 250 g and 500 g of substance were 
EUR 672.37 (52), EUR 4 464.29 (53) and 
EUR 7 142.86 (54)
The precursors NPP and 4-ANPP which can be used to 
synthesize acryloylfentanyl are offered from g to bulk 
(multi-kilogram) quantities on the internet from dozens 
of suppliers. For the purposes of illustration, prices for 
the immediate precursor 4-ANPP range from USD 75 per 
100 g to USD 5 000 per 1 kg.
Prevalence of use
No studies were identified that have investigated the 
prevalence of use of acryloylfentanyl in the general 
population, but the available information does not 
suggest wide use of the substance. Given its 
pharmacology, and, that it is sold openly as a ‘legal’ 
replacement to illicit opioids, it would be expected that 
those looking for substitutes for opioid analgesics, which 
would include individuals who use illicit opioids, such as 
heroin and/or prescription opioids, may seek out 
acryloylfentanyl and other fentanils. It also appears that 
there is interest in this substance by some psychonauts.
According to information from Swedish Police on 
807 buyers of the acryloylfentanyl, the substance is 
used mostly by men (80 %) aged 21 to 41 years. No 
further details were provided.
A total of three small seizures of acryloylfentanyl that 
also contained carfentanil and heroin were reported by 
Latvia. The overall significance of these seizures is 
unclear; however, the identification of carfentanil is of 
serious concern given its potency. In addition, the 
identification of heroin in the seizures may suggest that 
acryloylfentanyl is being supplied through the illicit 
heroin/opioid market.
(52) Available at: http://valhallaxmn3fydu.onion.rip/products/33602 
(accessed: 8 October, 2016).
(53) Available at: http://valhallaxmn3fydu.onion.rip/products/33603 
(accessed: 8 October, 2016).
(54) Available at: http://valhallaxmn3fydu.onion.rip/products/33604 
(accessed: 8 October, 2016).
Section D. Health risks
D1. Acute health effects
D1.1. Animal data
Data on the acute toxicity of acryloylfentanyl is limited to 
a single study in mice. This study reported that 
intraperitoneal injection of 25 mg/kg of acryloylfentanyl 
caused a transient suppression of motor activity; while, 
at a dose of 50 mg/kg the drug produced convulsions 
1 hour after drug administration and 60 % lethality was 
observed from apparent respiratory depression (Essawi, 
1998, 1999). From these data, an acute mouse LD
50
 
value between 25 and 50 mg/kg upon intraperitoneal 
administration may be suggested. While no comparative 
standard was used in this particular study, data from 
other studies on fentanyl suggest that the acute toxicity 
of acryloylfentanyl is similar to that of fentanyl.
What is the toxicological relevance of the acrylamide 
moiety of acryloylfentanyl?
Expecting that the reactive acrylic moiety could 
irreversible modify even inactivate the opioid receptor 
protein by virtue of a conjugate addition (‘Michael 
addition’) of nucleophilic amino acid side chains, 
especially sulfhydryl groups of cysteines, in and around 
the fentanyl-binding pocket, acryloylfentanyl was one of 
the fentanyl analogues designed as potential, covalently 
binding affinity labels for the receptor (Maryanoff et al., 
1982). Yet, in spite of having high affinity to opioid 
receptors (Table 2), acryloylfentanyl did not exhibit 
irreversible covalent binding in vitro (55,56).
Interestingly, the structurally related 〈- and 
®-chloroacryloyl analogues of fentanyl (57) while 
chemically reactive in solution (58) were weak opioid 
receptor ligands and failed to bind covalently to the 
receptor protein in vitro (respective IC
50
 values were 
69 and 60 nM) (Archer et al., 1985). The sustained 
antinociceptive activity observed in a recent study 
(Essawi, 1999) is thus unlikely related to the ‘reactivity’ 
of the acrylamide moiety of acryloylfentanyl.
(55) After incubation, acryloylfentanyl could completely be ‘washed out’ 
from the receptor preparation; the recovered receptor was then able 
to bind radiolabeled naltrexone indicating reversible binding of the 
drug.
(56) Similar non-irreversible binding was observed for an acrylamide 
derivative of naltrexamine (Archer et al., 1985).
(57) Respective alternative names: 2- and 3-chloropropenamide 
analogues of fentanyl.
(58) As estimated by the rate of Michael addition of 
4-methoxybenzenethiol to the chloroacryloyl species.
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Although recent studies indicate that acrylamides may 
target sulfhydryl or hydroxy residues of proteins 
(LoPachin and Gavin, 2012; Jöst et al., 2014), the actual 
irreversible (covalent) binding of the acryloyl moiety 
seems to depend on the chemical reactivity of the 
acrylamide moiety on one hand and on the spatial 
orientation of the potentially reactive ligand at the 
binding site, in particular on the molecular 
microenvironment, that is on the presence and 
accessibility of sulfhydryl groups at the binding pocket, 
on the other (see, for example Archer et al., 1985) (59).





a wide range of industrial uses, especially in the 
manufacture of various polymers; it is also formed 
during high-temperature cooking thus may be present in 
food. Acrylamide has been shown to be a skin irritant, 
neurotoxic, mutagenic and is considered to be 
a probable carcinogen in humans (Xu et al., 2014) (60). 
There is, however, little information on the acute or 
chronic toxic properties of N-phenylacrylamide-related 
substances.
It must be noted that the polymerisation processes 
involving acrylamide or other acrylic type substances 
require photochemical or free radical initiation, thus 
spontaneous polymerisation of acryloylfentantyl in the 
body can be ruled out. Whether any ‘biochemical’ 
initiator could be involved in the observed long-lasting 
activity in vivo (Section A.2) of acryloylfentanyl can only 
be speculated. It must also be noted that no stability 
studies have been carried out with acryloylfentanyl.
D1.2. Human data
No clinical studies were identified that have examined 
the acute health effects of acryloylfentanyl and/or its 
metabolites in humans. However, the comparable 
pharmacology of acryloylfentanyl and fentanyl in 
preclinical studies suggests some toxicological 
similarity. For fentanyl the estimated human lethal dose 
could be as low as 2 mg when injected intravenously 
(Marquardt et al., 1995; see also Baselt, 2000; Reeves 
and Ginifer, 2002; Moffat et al., 2011).
Data from serious adverse events associated with 
acryloylfentanyl are discussed in Section D.1.2.2. Based 
on the data reported, the clinical features presented in 
cases of intoxication suspected to involve 
(59) While chloroacryloyl fentanyl analogues were reversible opioid 
receptor ligands, chloroacryloyl derivatives of naltrexamine bound 
irreversibly to the receptor protein (Archer et al., 1985).
(60) For useful references, see: https://en.wikipedia.org/w/index.
php?title=Acrylamide&oldid=742413264
acryloylfentanyl appear to be similar to those found with 
fentanyl and other opioid analgesics. These include the 
opioid triad of miosis, unconsciousness, and respiratory 
depression; nausea and vomiting, dizziness were also 
reported.
Acute intoxications reported by the Member States
A total of 21 acute intoxications associated with 
acryloylfentanyl were reported by one country: 
Sweden (61). All 21 cases related to acute non-fatal 
intoxications that presented to hospital emergency 
departments between March and August 2016 and 
reported to the Swedish Poison Information Centre. All 
were classed as suspected cases as there was no 
analysis of biological samples or other samples used by 
the patients (62).
In all cases the patient either reported that they had 
used acryloylfentanyl and/or medical staff had other 
information to suggest that they had consumed 
acryloylfentanyl.
In all cases the patient either reported that they had 
used acryloylfentanyl and/or medical staff had other 
information to suggest that they had consumed 
acryloylfentanyl.
Demographics
Of the acute intoxications, 18 (86 %) were male, three 
(14 %) were female. The mean age of the male cases for 
which an age was known (n=7) was 35 years (median 
29) and ranged from 22 to 44 years; for the female cases 
the ages were 22, 23, and 40 years.
Substances analytically identified in biological samples
None of the 21 cases were subject to analytical 
confirmation in biological samples.
(61) In addition, aggregated data regarding 7 non-fatal intoxications 
suspected to involve acryloylfentanyl occurring between March and 
September 2016 was also reported by the Swedish Poisons 
Information Centre. Acryloylfentanyl was not analytically confirmed in 
any of these cases. As this is aggregated data, no further details 
regarding the individual cases are known and it is therefore possible 
that some of these cases are duplicates of the 21 acute intoxications. 
These aggregated cases are not considered further in the analysis.
(62) For the purposes of this report the following definitions are used. 
Confirmed case means that information on exposure to 
acryloylfentanyl is available from analytical confirmation in one or 
more biological samples taken from a patient. Probable case means 
that information on exposure was only available from the analytical 
confirmation of acryloylfentanyl in a drug sample and that there is 
a reasonable probability that the patient was exposed to that drug 
sample. Suspected case means that information on exposure is 
typically limited to the name of the substance that the patient 
believes that they have consumed and/or from packages containing 
the drugs that the patient is thought to have consumed. As a result, 
information on the features of the intoxication from probable and 
suspected cases should be interpreted with caution.
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In some cases, users reported taking other substances: 
4-methylmethylphenidate, 3-hydroxyphenazepam, 
4-chloro-PPP, N-ethylhexedrone, amphetamine, 
oxycodone, buprenorphine, ethanol and 4-chloro-PHP.
Seriousness of the intoxications
Data on the seriousness of the intoxication as classified 
by the poison centre were reported for all 21 cases:
 § In 13 out of the 21 cases the seriousness of the 
intoxication was classified as life threatening and 
required treatment in hospital.
 § In 8 out of the 21 cases the intoxication was classified 
as non-life threatening but required treatment in 
hospital.
 § Information on the length of hospital stay was not 
available in the cases.
Clinical features
Data on clinical features/ symptoms related to the 
21 acute intoxications included: miosis, 
unconsciousness, and respiratory depression; 
tachycardia, somnolence, restlessness, and nausea/
vomiting were also reported. However, the lack of 
analytically confirmed drugs hinders the interpretation of 
this as other drugs may have caused or contributed to 
the symptoms observed. Nevertheless, such symptoms 
appear to be consistent with use of an opioid analgesic.
The use of the antidote naloxone was reported in 8 of the 
cases, with apparent reversal of the poisoning reported 
in 4 of these cases (patients ‘woke up’). This is 
suggestive of poisoning with an opioid analgesic.
Route of administration and physical form of the 
substance/product
Data on the route of administration was available for 
17 out of 21 cases. The substance was predominantly 
taken nasally (presumably as a nasal spray), snorted, or 
taken orally, with one case involving injection of a ‘nasal 
solution’. The substance was typically consumed as 
a nasal solution, and to a lesser extent as a powder or 
tablets.
Acute intoxications identified from other sources
One paper was identified that reported that the Swedish 
STRIDA project has detected an unspecified number of 
confirmed acute intoxications associated with 
acryloylfentanyl. No further details were provided 
(Helander & Bäckberg, 2016).
Deaths reported by the Member States
A total of 47 analytically confirmed deaths associated 
with acryloylfentanyl were reported by three Member 
States: Denmark (1 case), Estonia (3), and Sweden (43).
No additional information is currently available for the 
deaths reported by Estonia. Therefore, the analysis 
below is restricted to the 44 deaths reported by 
Denmark and Sweden.
Demographics
Of the 44 deaths, 38 were male (86 %) and six were 
female (14 %). The mean age of the male decedents was 
31 years (median 29) and ranged from 19 to 54 years; 
the mean age of the female decedents was 42 years 
(median 43) and ranged from 29 to 50 years.
Number of deaths by year
The deaths occurred between April and December 2016. 
More than 70 % of the deaths (32) occurred between 
June and August 2016; with 10 deaths in June, 9 in July, 
and 13 in August.
Cause of death and toxicological significance
In at least 40 deaths, acryloylfentanyl was either the 
cause of death or is likely to have contributed to death 
(even in presence of other substances); in two of these 
deaths acryloylfentanyl was the sole drug present. 
Acryloylfentanyl was quantified in all cases. Post-
mortem blood concentrations between 0.01 and 
5.0 ng/g blood were recorded (mean 0.78; median: 0.19) 
(somewhat but not exactly equivalent to µg/L).
A range of other substances were found in the deaths, 
including: benzodiazepines, zopiclone, gabapentinoids 
(pregabalin and gabapentin), ethanol, cannabinoids 
(including synthetic cannabinoids), synthetic cathinones, 
amphetamines, antidepressants, antipsychotics. In 
38 cases, acryloylfentanyl was the sole opioid present. 
In the remaining six cases, other opioids detected were 
buprenorphine (2 deaths), oxycodone (1); oxycodone 
and hydrocodone (1); oxycodone and 4-fluoro-
isobutyrfentanyl (1); and, 4-chloro-isobutyrfentanyl (1).
Overall, whilst other substances may have contributed to 
some toxicity in their own right, a synergistic effect with 
acryloylfentanyl would have been likely (e.g. other CNS 
depressants such as ethanol, benzodiazepines, z-drugs, 
gabapentinoids, and opioids, etc.). Nevertheless, the 
pharmacological opioid nature of acryloylfentanyl means 
the primary toxic contribution could be attributed to the 
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drug and death may not have occurred if acryloylfentanyl 
had not been used.
In all deaths there was a lack of information regarding 
any symptoms experienced by the deceased prior to 
death.
Circumstances of death
Information regarding the circumstances of death was 
reported for 43 out of 44 cases. In more than 70 % of the 
cases (32), the individuals were found dead or died in 
a home environment (their own or someone else’s); with 
five found dead in bed. Consequently, it was not possible 
to identify or evaluate ante-mortem symptoms (especially 
in relation to acute intoxications); however, in three cases 
the deceased was described as being unconscious prior 
to death, and in one of these cases it was reported that 
the deceased lost consciousness 10 minutes after using 
acryloylfentanyl. In a further case, the deceased was 
described as being found on the floor with a ‘seizure 
disorder’ and that attempts at resuscitation failed.
Deaths identified from other sources
No other deaths were identified from other sources.
D2. Chronic health effects
D2.1. Animal data
No studies were identified that have investigated the 
chronic health effects of acryloylfentanyl in animals.
D2.2. Human data
No studies were identified that have investigated the 
chronic health effects of acryloylfentanyl in humans.
D3. Factors affecting public health risks
D3.1. Availability and quality of the new psychoactive 
substance on the market
Acryloylfentanyl is sold as a drug in its own right and 
offered for sale by internet retailers and for sale in both 
retail and wholesale quantities. It has been sold as 
a ‘research chemical’ in several physical forms, including 
as powders and ready-to-use nasal sprays.
Limited information from seizures of acryloylfentanyl 
suggests that acryloylfentanyl may have been sold on 
the illicit drug market, including the illicit opioid/heroin 
market.
D3.2. Availability of the information, degree 
of knowledge and perceptions amongst users 
concerning the psychoactive substance and 
its effects
There is limited information on user websites regarding 
the effects and adverse effects related to the use of 
acryloylfentanyl. The users appeared to be generally 
aware of the opioid-like (wanted and unwanted) effects 
of this substance.
Some discussions on these sites describe 
acryloylfentanyl as ‘longer lasting’ after dosing than 
other new synthetic opioids.
D3.3. Characteristics and behaviour of users
No studies were identified that have examined the 
characteristics and behaviours of users of 
acryloylfentanyl. The available information, including 
deaths reported by the Member States and from user 
websites, suggests that acryloylfentanyl is typically used 
in the home environment.
Some users may seek out acryloylfentanyl because it 
was sold openly as a ‘legal replacement’ to illicit opioids; 
others may be experimenting with this opioid (so called 
psychonauts) to explore possible novel effects; whilst 
others still may seek to self-medicate pain or opioid-
withdrawal symptoms. It is possible that some users, 
particularly those consuming acryloylfentanyl in 
mixtures with other illicit opioids such as heroin, may not 
be aware that they are consuming the substance.
Information from the deaths reported to the EMCDDA 
highlights, that, besides acryloylfentanyl, other opioids 
were only detected in six of the 44 deaths (13.6 %). This 
suggests that a majority of the decedents may have had 
no tolerance to opioids. In addition, the data also shows 
that polydrug use was common, including the use of 
other CNS depressants (Section D1.2).
D3.4. Nature and extent of health consequences
The limited information available on the pharmacology, 
dependence and abuse potential, and acute health 
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effects of acryloylfentanyl have been discussed above 
(Section A2, Section B, Section D1 and Section D2).
While the pharmacology and toxicology of 
acryloylfentanyl largely remains unstudied, the available 
data, including its structural similarity to fentanyl, 
suggests that it is a potent opioid analgesic.
Among other adverse effects, opioid analgesics, such as 
fentanyl, produce dose-dependent respiratory 
depression. This risk is greater in opioid-naïve persons. 
Similar to other fentanils in overdose, the most serious 
acute risk arising from the use of acryloylfentanyl 
appears to be from profound and rapid respiratory 
depression, which can lead to apnoea, respiratory arrest, 
and death. This risk may be exacerbated given:
 § the difficulty of diluting fentanils (63);
 § the lack of experience of users with this new 
substance (in terms of a lack of familiarity with the 
effects and dose of the substance);
 § the concomitant use of other CNS depressants (such 
as other opioids, benzodiazepines, gabapentanoids, 
and ethanol (alcohol));
 § in some cases no apparent tolerance to opioids; and,
 § the environment in which the substance is used — 
typically in the home environment.
The majority of the deceased were found dead at home, 
including a number that were found dead in bed. It is 
reasonable to assume that in at least some of these 
cases the poisoning with acroylfentanyl was so severe 
that they were unable to call for help.
Importantly, it is also reasonable to assume that the 
antidote naloxone will reverse poisoning (overdose) 
caused by exposure to acryloylfentanyl. However, larger 
than normal as well as repeated doses may be required 
to fully reverse poisoning due to the potency of the 
fentanils, their half-lives, and the dose used (CDC, 2013; 
FDA, 2016). Clinical and community experience in 
treating poisonings caused by exposure to fentanils 
supports this assertion (Klar et al., 2016; Sutter et al., 
2017). Stocks and availability of the antidote naloxone, 
as well as adequacy of training in how to resuscitate 
poisoned patients may need to be assessed.
In a recent outbreak of poisonings in California, United 
States, which was caused by counterfeit analgesic 
medicines containing large doses of fentanyl (Sutter et 
al., 2017), it was highlighted that:
 § Sufficient antidote stocking was an important factor 
as the supplies of naloxone at the hospital were 
(63) This is also reflected in data from seizures of tablets containing 
fentanils which have shown large variability in the amount of the 
substance present (de Boer et al., 2003).
quickly depleted because of the large number of 
patients that presented over a short period of time, as 
well as the need of some patients for several 
milligrams of naloxone as bolus dosing and prolonged 
infusion times.
 § The hospital required emergency deliveries of 
naloxone to keep supplies sufficient for patient care.
 § A notable clinical difference observed was not only 
that some patients required prolonged naloxone 
infusions but also the recurrence of respiratory 
depression in the hospital after 8 hours of 
observation without naloxone.
In addition to users, accidental exposure of 
acryloylfentanyl and other fentanils — such as skin 
contact, inhalation, or ingestion — pose a serious risk of 
poisoning to the public, law enforcement, emergency 
personnel, as well as medical and forensic laboratory 
personnel (Section A).
Adding to the challenges posed by the fentanils is 
evidence from Europe, the United States, and Canada 
that they are being sold to unsuspecting users in/as 
heroin, counterfeit medicines (including commonly used 
opioid analgesics and benzodiazepines), cocaine, and 
other illicit drugs (64). As users will be unaware of this, it 
increases the risk of severe and fatal poisoning in both 
opioid users and especially other groups who may have 
no existing tolerance to opioids (Klar et al., 2016; 
HCCCSF, 2016a; HCCCSF, 2016b; SFDPH, 2015; 
Tomassoni et al., 2017). Non-opioid users are unlikely 
neither to be aware of these risks nor to have access to 
community-based naloxone programmes, including 
take-home naloxone (EMCDDA, 2015; EMCDDA, 2016).
D3.5. Long-term consequences of use
There is no data regarding the long-term consequences 
of using acryloylfentanyl. 
D3.6. Conditions under which the new psychoactive 
substance is obtained and used, including context-
related effects and risks
There is very limited data on the conditions which 
acryloylfentanyl is obtained and used. It appears 
acryloylfentanyl has been sold on the surface web and 
darknet marketplaces, typically as powders and ready-
to-use nasal sprays. 
(64) In three seizures reported to the EMCDDA, acryloylfentanyl was 
detected with carfentanil and heroin. This may suggest that 
acryloylfentanyl is being sold on the illicit opioid market, including 
heroin market (Section C).
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Limited information suggests that it may also have been 
sold on the illicit drug market, including the illicit opioid/
heroin market in some countries.
In more than 70 % of the deaths reported to the 
EMCDDA, the individuals were either found dead or died 
in a home environment (their own or someone else’s).
Data reported to the EMCDDA suggests that ready-to-
use nasal sprays and e-liquids containing fentanils are 
increasing in availability. It will be important to study 
what effect, if any, these products have had on 
increasing physical availability, attractiveness, and 
social acceptance to existing and new groups of users.
Section E. Social risks
While there have been no studies on the social risks of 
acryloylfentanyl, it is likely that some of the risks are 
similar to those associated with opioids such as fentanyl 
and heroin.
E1. Individual social risks
There is no information on whether the use of 
acryloylfentanyl causes individual social risks; however, 
they may have some similarities with those associated 
with illicit opioids, including fentanyl and heroin. These 
may impact on education or career, family or other 
personal and social relationships and may result in 
marginalisation.
E2. Possible effects on direct social 
environment 
There is no information on the possible effects of 
acryloylfentanyl on the direct social environment; 
however, they may have some similarities with those 
associated with the use of illicit opioids.
E3. Possible effects on society as a whole
There is no specific information on the possible effects of 
acryloylfentanyl on society as a whole. 
As discussed above, accidental exposure of 
acryloylfentanyl and other fentanils — such as skin 
contact, inhalation, or ingestion — also poses a serious 
risk of poisoning to those who may come into contact 
with the substances. This includes the family and friends 
of users, law enforcement, emergency personnel, 
medical and forensic laboratory personnel as well as 
custodial settings and postal services. Where required, 
these risks should be assessed and appropriate 
procedures, training, and protective measures should be 
implemented. This may include training in resuscitation 
and adequate provision of naloxone to reverse poisoning. 
E4. Economic costs
There are no data on the effects of acryloylfentanyl in 
respect to its health and social costs. However, it is likely 
that even at low prevalence this drug has the potential to 
generate relatively high costs to health services.
E5. Possible effects related to the cultural 
context, for example marginalisation
There is no specific data on the possible effects of 
acryloylfentanyl related to the cultural context.
E6. Possible appeal of the new psychoactive 
substance to specific population groups within 
the general population
Whilst no specific examples are available on the 
possible appeal of acryloylfentanyl to specific user 
groups, it is reasonable to assume acryloylfentanyl may 
be sought by those looking for substitutes for illicit 
opioids, such as heroin and/or prescription opioids. 
In addition, concerns exist over novel dosage forms — 
such as ready-to-use nasal sprays and e-liquids for 
vaping — which have the potential to make the use of 
fentanils easier (with similar effects to injecting) and 
more socially acceptable. Further research is required 
on this topic to better understand the risks.
Section F. Involvement of organised 
crime
F1. Evidence that criminal groups are 
systematically involved in production, trafficking 
and distribution for financial gain
No information has been received by Europol indicating 
production of acryloylfentanyl within the EU.
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F2. Impact on the production, trafficking and 
distribution of other substances, including 
existing psychoactive substances as well as new 
psychoactive substances
There is no information on the impact of acryloylfentanyl 
on the production, trafficking and distribution of other 
substances, including existing psychoactive substances 
as well as new psychoactive substances.
F3. Evidence of the same groups of people being 
involved in different types of crime
No information has been received by Europol of 
evidence of the same groups of people being involved in 
different types of crime in connection with 
acryloylfentanyl.
F4. Impact of violence from criminal groups on 
society as a whole or on social groups or local 
communities (public order and safety)
No specific information has been received by Europol on 
incidents of violence in connection with acryloylfentanyl.
F5. Evidence of money laundering practices, 
or impact of organised crime on other 
socioeconomic factors in society
No specific information has been received by Europol on 
incidents of money laundering or impact of organised 
crime on other socioeconomic factors in society in 
connection with acryloylfentanyl.
F6. Economic costs and consequences (evasion 
of taxes or duties, costs to the judicial system) 
There are no published data to be able to determine the 
impact of acryloylfentanyl in this area.
F7. Use of violence between or within criminal 
groups
There are no published data to be able to determine the 
impact of acryloylfentanyl in this area.
F8. Evidence of strategies to prevent 
prosecution, for example through corruption or 
intimidation
There are no published data to be able to determine the 
impact of acryloylfentanyl in this area.
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Council Decision
published in OJ L 251/21, on 29.9.2017
COUNCIL IMPLEMENTING DECISION (EU) 2017/1774 of 25 September 2017 
on subjecting N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide (acryloylfentanyl) 
to control measures
THE COUNCIL OF THE EUROPEAN UNION,
Having regard to the Treaty on the Functioning of the European Union,
Having regard to Council Decision 2005/387/JHA of 10 May 2005 on the information 
exchange, risk-assessment and control of new psychoactive substances (1), and in 
particular Article 8(3) thereof,
Having regard to the proposal from the European Commission,
Having regard to the opinion of the European Parliament (2),
Whereas:
(1) A risk assessment report on the new psychoactive substance N-(1-phenethylpiperidin-
4-yl)-N-phenylacrylamide (acryloylfentanyl) was drawn up in accordance with Decision 
2005/387/JHA by a special session of the extended Scientific Committee of the European 
Monitoring Centre for Drugs and Drug Addiction, and was subsequently submitted to the 
Commission and to the Council on 24 February 2017.
(2) Acryloylfentanyl is a synthetic opioid. It is structurally similar to fentanyl, a controlled 
substance widely used in medicine as an adjunct to general anaesthesia during surgery 
and for pain management. The available data suggest that acryloylfentanyl is a potent and 
long-lasting antinociceptive agent acting on the opioid system.
(3) Acryloylfentanyl has been available in the Union since at least April 2016 and has been 
detected in six Member States. In most cases where it has been seized, the substance 
was in liquid form, but other forms such as tablets, powders and a capsule have also been 
detected. The detected quantities are relatively small, but should be considered in the 
context of the high potency of the substance.
(4) Three Member States have collectively reported 47 deaths associated with 
acryloylfentanyl. In at least 40 deaths, acryloylfentanyl was the cause of death or is likely 
to have been a contributing cause of death. In addition, more than 20 acute intoxications 
suspected to be due to acryloylfentanyl have been reported.
(5) There is no information to suggest the involvement of organised crime in the 
manufacture, distribution, trafficking or supply of acryloylfentanyl within the Union. The 
available data suggest that most of the acryloylfentanyl on the market in Europe has been 
produced by chemical companies based in China.
(6) Acryloylfentanyl is sold as ‘research chemical’, typically as a powder or as ready-to-use 
nasal sprays. It is sold in small and wholesale amounts. Limited information from seizures 
suggests that acryloylfentanyl may have also been sold on the illicit opioid market.
(1) OJ L 127, 20.5.2005, p. 32.
(2) Opinion of 13 September 2017 (not yet published in the Official Journal).
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(7) Acryloylfentanyl is not listed for control under the 1961 United Nations Single 
Convention on Narcotic Drugs or under the 1971 United Nations Convention on 
Psychotropic Substances. The substance is not currently under assessment by the United 
Nations system.
(8) Acryloylfentanyl has no established or acknowledged human or veterinary medical use. 
Apart from its use in analytical reference materials and in scientific research into its 
chemistry, pharmacology and toxicology in response to its emergence on the drug market, 
there is no indication that it is being used for other legitimate purposes.
(9) The risk assessment report reveals that there is limited scientific evidence available on 
acryloylfentanyl, and observes that further research would be needed. However, the 
available evidence and information on the health and social risks that the substance poses 
provide sufficient grounds for subjecting acryloylfentanyl to control measures across the 
Union.
(10) Only nine Member States control acryloylfentanyl under national drug control 
legislation, while two other Member States use other legislative measures to control it. 
Therefore, subjecting this substance to control measures across the Union would help 
avoid the emergence of obstacles in cross-border law enforcement and judicial 
cooperation, and would help protect from the risks that its availability and use could pose.
(11) Decision 2005/387/JHA confers upon the Council implementing powers to submit 
new psychoactive substances to control measures across the Union in order to ensure 
a quick and expertise-based response at Union level to the emergence of such substances 
that have been detected and reported by the Member States. As the conditions and 
procedure for triggering the exercise of such implementing powers have been met, an 
implementing decision should be adopted in order to subject acryloylfentanyl to control 
measures across the Union.
(12) Denmark is bound by Decision 2005/387/JHA and is therefore taking part in the 
adoption and application of this Decision, which implements Decision 2005/387/JHA.
(13) Ireland is bound by Decision 2005/387/JHA and is therefore taking part in the 
adoption and application of this Decision, which implements Decision 2005/387/JHA.
(14) The United Kingdom is not bound by Decision 2005/387/JHA and is therefore not 
taking part in the adoption of this Decision, which implements Decision 2005/387/JHA, 
and is not bound by it or subject to its application,
HAS ADOPTED THIS DECISION:
Article 1
The new psychoactive substance N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide 
(acryloylfentanyl) shall be subjected to control measures across the Union.
Article 2
By 30 September 2018, Member States shall take the necessary measures in accordance 
with their national law to subject the new psychoactive substance referred to in Article 1 
to control measures and criminal penalties, as provided for under their legislation, in 
compliance with their obligations under the 1971 United Nations Convention on 
Psychotropic Substances.
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Article 3
This Decision shall enter into force on the day following that of its publication in the Official 
Journal of the European Union.
This Decision shall apply in accordance with the Treaties.
Done at Brussels, 25 September 2017.
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